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Cystic fibrosis (CF) is an inherited disease characterized by impaired mucociliary clearance 
of thick mucus and persistent bacterial infection in the lungs. Nitric oxide (NO), an endogenously 
produced radical with integral roles in the mammalian immune response to foreign pathogens, 
holds promise as a CF therapy. Inhalation of exogenous NO-releasing biopolymers represents an 
attractive therapeutic strategy as NO release can be sustained for hours, allowing for near 
continuous delivery. Alginate is particularly promising for this application due to its water 
solubility, mucus-altering ability, and biocompatibility. Herein, we evaluated the utility of NO-
releasing alginates as a dual-action (i.e., mucolytic and antibacterial) CF therapeutic.  
Low (~5 kDa) and high (~300 kDa) molecular weight alginate were first modified with a 
series of small molecule alkyl amines via carbodiimide chemistry to store and release NO, with 
release kinetics dependent on the precursor amine structure. The liberated NO showed bactericidal 
activity against Pseudomonas aeruginosa and Staphylococcus aureus with pathogen eradication 
efficiency dependent on both molecular weight and NO-release kinetics. Toxicity against human 
respiratory epithelial cells proved negligible at NO-releasing alginate concentrations required to 
achieve biofilm eradication. 
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The excessive production of thick mucus in CF leads to airway obstruction and provides a 
suitable environment for bacteria colonization. The impact of NO-releasing alginates on the 
viscoelasticity of human bronchial epithelial mucus was investigated using parallel plate rheology. 
The efficacy of the NO-releasing alginates was shown to be dependent on molecular weight, NO-
release kinetics, and dose. Nitric oxide-releasing alginates also achieved greater reduction in 
mucus rheology than both NO-releasing chitosan, a biocompatible cationic polymer, and N-acetyl 
cysteine, a conventional mucolytic agent.  
Biofilm-forming pathogens, the major contributor to mortality in CF, are difficult to treat 
due to additional protection provided by both the biofilm exopolysaccharide matrix and mucus in 
the airways. The antibiofilm efficacy of NO-releasing alginates were evaluated against P. 
aeruginosa, Burkholderia cepacia complex, S. aureus, and methicillin-resistant S. aureus biofilms 
under CF-relevant conditions. The NO-releasing alginates were highly antibacterial against the 
four pathogens, with biocidal efficacy dependent on NO-release kinetics. Relative to tobramycin 
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CHAPTER 1: DESIGNING A NOVEL DUAL-ACTION NITRIC OXIDE-BASED 
THERAPEUTIC FOR CYSTIC FIBROSIS 
1.1 Cystic fibrosis pathogenesis 
 Cystic fibrosis (CF) is a lethal autosomal disorder affecting over 70,000 people 
worldwide.1,2 The disease results from mutations in the CF transmembrane conductance regulator 
(CFTR), which controls ion (i.e., chloride) transport in epithelial membranes.3–5 Defects in the 
CFTR lead to dysregulation of epithelial fluid transport and affect multiple organs, such as the 
pancreas, liver, kidneys, and the lungs. However, the most debilitating effects are observed in the 
respiratory tract. In the airways, loss of CFTR function causes dehydration of the airway surface 
liquid (ASL) and ultimately interferes with mucociliary clearance.6–8 As a result, thick stagnant 
mucus accumulates and obstructs the airways. Nutrients in mucus foster a suitable environment 
for the colonization of various bacterial pathogens, including Pseudomonas aeruginosa.9 P. 
aeruginosa infections in particular lead to significant morbidity and mortality in CF patients. 
Persistent colonization by pathogens in general elicit a strong host inflammatory response and lung 
function degradation.10 This vicious cycle (Figure 1.1) results in respiratory failure that accounts 
for ~90% of patient mortality.10–12 
1.1.1 Airway surface liquid in healthy lungs 
In healthy lungs, the ASL acts as an innate defense barrier against inhaled particles (e.g., 
dust, pollen, chemical irritants) and invading pathogens (e.g., bacteria, viruses).7,13,14  The ASL is 















mucus layer from the epithelial surface of the airways.7  Mucus is produced and secreted by 
different types of cells in the body, with the goblet cells responsible for the production of  
mucin glycoproteins, the main components of mucus.7,15 The mucus layer is composed of 95% 
water and 2% mucins (the component that dictates its gel-like properties), with the remaining 3% 
made up of proteins, lipids, and inorganic salts.15,16 As a result, mucus is able to entrap inhaled 
foreign materials and transport them out of the lungs through the motion of ciliated surfaces within 
the airways.7,16 The PCL is ~7 µM thick and has a low viscosity and a tightly regulated ionic 
content; these properties allow the ciliated epithelial cells of the airways to beat unrestricted and 
propel the mucus layer, a process called mucociliary clearance (Figure 1.2).7,17 Epithelial cells are 
closely packed, forming a dense field of cilia, interrupted only by islands of goblet cells and mucus 
gland openings.7 The PCL thickness allows for optimal contact between cilia and the mucus layer.7 
The cilia are mostly immersed in the PCL, with only their tips embedded in the mucus layer. The 
cilia beat in a synchronized, wave-like manner to propel mucus towards the trachea.7,18  
To regulate the thickness and volume of the PCL, proper ionic composition of the PCL is 
required.7,18 The necessary ionic concentration is maintained through the absorption of sodium 
(Na+) via the epithelial sodium channel (ENaC) and secretion of chloride (Cl-) in the airways by 
the calcium-activated Cl- channel (CaCC) and the CFTR.19  When the airway surface is dehydrated, 
water loss first occurs in the mucus layer due to its lower osmotic modulus,8 increasing mucin 
glycoprotein concentration which results in a more viscoelastic layer. Further dehydration leads to 
water loss in both the mucus layer and the PCL, resulting in compression of the PCL.8 The cilia 
fail to effectively beat, as they are inhibited by the more viscous mucus layer.8,16,18,19 (Figure 1.3).19 













Figure 1.2 The airway surface liquid (ASL), composed of the mucus layer and the periciliary 
layer in healthy airways. Inhaled particles are trapped within the mucus layer and cleared from 















Figure 1.3 Dysregulation of ionic content in ASL impairs mucociliary clearance. In healthy 
airways, regulation of ionic content is maintained via the epithelial sodium channel (ENaC), 
which absorbs Na+, and the calcium-activated Cl- channel (CaCC) and the CFTR, which 
secretes Cl- in the airways. In CF airways, ionic content is dysregulated due to mutations in the 
CFTR chloride channel and results in the dehydration of both the mucus layer and the PCl. 
This leads to the collapse of the cilia in the PCL and failure to clear mucus in the lungs.  
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clearance. A defect in this mechanism results in pathophysiological changes of the ASL, 
characteristic of pulmonary diseases such as CF.7 
1.1.2 Mucus accumulation in CF airways 
In CF airways, a genetic defect in the CFTR causes chloride and sodium hyperabsorption, 
which dehydrates the ASL.7,16,20,21 Water loss increases mucus viscosity and dehydrates the PCL, 
resulting in cilia collapse and impaired mucociliary clearance (Figure 1.3).16,19  Failure to clear the 
abnormally thick mucus in the airways coupled with the continuous production of mucins by 
goblet cells further aggravates this problem.18 The depletion of the PCL also causes adhesion of 
the viscous mucus layer to the epithelial surface of the airways, rendering other methods of 
mechanical clearance (i.e., coughing) ineffective.7,18 The inability to remove the accumulated 
mucus, along with particles and microorganism trapped in it, facilitates chronic infection and 
inflammatory reactions in the CF lung.  
1.1.3 Bacterial lung infection in CF 
Cystic fibrosis is characterized by persistent bacterial infection. The CF microbiome is 
diverse, with Staphylococcus aureus and Haemophilus influenzae being prominent pathogens 
during infancy and adolescence, with Pseudomonas aeruginosa, Burkholderia cepacia complex, 
Stenotrophomonas maltophilia, and nontuberculous mycobacteria becoming more prominent 
during adulthood  (Figure 1.4).11,12,22,23 Chronic pulmonary infection accounts for ~90% of patient 
mortality. An understanding of the bacterial colonization within the CF lung is thus essential for 
the development of novel therapeutic strategies to combat severe infections. 
The CF pathogen most associated with patient mortality is P. aeruginosa.24 Colonization 














Figure 1.4 The CF microbiome described by pathogen prevalence as a function of age in the 
US. Reprinted with permission from the 2016 Patient Registry Annual Data Report to the 
Center Directors (CF Foundation). 
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Studies have shown that by age 20, ~80% of patients with CF have chronic P. aeruginosa infection, 
with each individual having phenotypically distinct isolates.12,22 The ability of this Gram-negative 
pathogen to genetically adapt to the CF lung microenvironment (e.g., hypoxic or anaerobic 
conditions present in the mucus layer) allows it to both evade the host immune response and 
develop resistance to clinically-relevant classes of antibiotics.6,26 In addition, P. aeruginosa forms 
biofilms in the lower respiratory tract.6,9 Biofilms are cooperative communities of bacteria that 
produce an exopolysaccharide (EPS) matrix that serves as a capsule to provide additional 
protection against the host immune response and antibacterial agents.6,9,27 A slower growth rate is 
adapted by bacteria in biofilms to ration limited nutrients, resulting in genetic alterations (e.g., 
lipopolysaccharide modification on the cell surface, the use of drug efflux pumps) that reduce the 
efficacy of antibacterial interventions (e.g., antibiotics).28–31 Despite a reported decline in the 
prevalence of P. aeruginosa over the past 10 years, the occurrence of multi-drug resistant (MDR) 
strains of P. aeruginosa still infects ~17% of patients with CF.22 As a result, the management of 
P. aeruginosa infections have become a critical part of CF treatment strategies. 
While colonization by P. aeruginosa dominates bacterial infections in the later years of CF 
patients, the most widespread infection in children is caused by Gram-positive S. aureus.12  A 
significant increase in the prevalence of S. aureus was noted from 2000 to 2010,22 possibly due to 
improved screening and detection methods, demanding for improved management strategies. 
Infections with S. aureus occur predominantly in the upper respiratory tract which serves as a 
reservoir for colonizing bacteria, eventually facilitating recurrent infections in the lower airways.11 
Similar to P. aeruginosa, adaptive strategies allow for the emergence of antibiotic-resistant strains 
of S. aureus, such as methicillin-resistant S. aureus (MRSA). Chronic respiratory infections with 
MRSA have been associated with severe pulmonary function decline in CF patients.32–35 
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Although less common than P. aeruginosa and S. aureus colonization, infection with 
Burkholderia cepacia complex (BCC) is associated with high patient mortality in CF.12,36,37 The 
BCC is a group of at least 17 closely related species, with Burkholderia cenocepacia and 
Burkholderia multivorans as the best-described causes of pulmonary infection in CF.23,38 Treating 
chronic infection with BCC is difficult, as the Gram-negative bacteria intrinsically demonstrate 
resistance to most conventional antibiotics.12,23 As such, combination therapy (i.e., concurrent 
treatment with multiple classes of antibiotics) has shown promise in vitro for addressing BCC 
infections.23,39–42 However, a clinical trial demonstrated no improved outcomes for combination 
therapy, indicating that the success of this type of treatment is still somewhat limited.40,43 Due to 
the severity of BCC infections and the limited potential for their eradication, patients with these 
infections are ineligible for lung transplantation.37,44 
1.1.4 Inflammation and lung degradation 
 Lung disease in CF is characterized by abnormal, chronic inflammation. Studies have 
suggested that inflammation occurs very early in the life of a CF patient (even in the absence of 
infection) as a result of immune dysregulation (e.g., unfolded CFTR stress response, abnormal 
innate and adaptive immunities).45–49 Other reports, however, have not supported this hypothesis 
and rather show that inflammation occurs as a direct consequence of chronic bacterial 
infection.45,50 Regardless of how the process is initiated, the neutrophil-dominated inflammatory 
response plays a prominent role in cyclical damage to the airways (Figure 1.1).45,51–53 Recruited 
neutrophils combat invading pathogens through the release of reactive oxygen species (ROS), 
reactive nitrogen species (RNS), and proteases.45,51–53 The overwhelming bacterial load present in 
CF lungs combined with the formation of biofilms reduces the efficacy of neutrophil phagocytosis, 
resulting in persistent infection. Consequently, the inflammatory response to the bacterial burden 
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in the lungs intensifies.45,53 The high concentrations of ROS released by the accumulated 
neutrophils and the influx of proteases, such as neutrophil elastase (NE), cause structural damage 
to the respiratory epithelium.45,51–53 Excessive production of proteases further impairs 
phagocytosis, allowing infection to persist.45,51,52 A self-perpetuating cycle of infection and 
inflammation initiates and facilitates irreversible lung damage, ultimately leading to lung disease 
in CF (Figure 1.1).52 
 
1.2 Current treatment methods for cystic fibrosis 
To date, there is no cure for cystic fibrosis as any curative treatment for CF must restore 
function to the impaired CFTR channel. With more than 2,000 known mutations in the CFTR gene 
found to correlate with CF, only select patients benefit from the use of CFTR modulators for 
slowing disease progression.25 Instead, most efforts have been directed towards symptomatic 
treatment of the disease in order to benefit a larger pool of patients. A typical daily regimen for a 
CF patient includes treatment with hypertonic saline and a combination of mucolytic, antibiotic, 
and anti-inflammatory agents. These treatments aim to rehydrate the ASL, decrease mucus 
viscoelasticity, combat infection, and decrease inflammation. Even with these concurrent 
treatments, normal lung function is not restored. When lung degradation fails to be mitigated, lung 
transplantation becomes a necessary option. While a cure for CF has yet to be discovered, these 
treatments have raised the median age of survival from 14 years in 1969 to 40 years in 2016.22  
1.2.1 CFTR modulators 
A causative treatment for CF involves the use of CFTR modulators to address the 
underlying genetic defects associated with the disease. This type of treatment is targeted towards 
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a specific class of mutations.22,25,54 Mutations associated with CF are broken down into classes 
based on their resulting functional impact. The first class of mutations (Class I) include 
biosynthetic defects that lead to an absence of functional CFTR protein. Class II mutations, on the 
other hand, affect intracellular trafficking of the CFTR. In this case, the CFTR protein is present 
but misfolded, thus keeping it from reaching the cell surface. The Class II mutations also includes 
F508del, the most common mutation in both U.S. and European patients. Other defects in the 
CFTR include anomalous gating in the channel that limits ion transport (Class III), abnormal 
conductance of chloride (Class IV), and splicing mutations, that reduce the level of CFTR gene 
transcription (i.e., Class V). The U.S. Food and Drug Administration (FDA) approved the first 
CFTR modulator in 2012 with Ivacaftor (trade name Kalydeco), which targets the G551D mutation 
falling under Class III. Ivacaftor improves the transport of Cl- through the ion channel by directly 
binding to the channels to induce a non-conventional mode of gating.55 While this mutation is the 
third most common type worldwide, it is only found in ~4-5% of CF patients.56 As of 2012, 
Ivacaftor has been approved for patients with additional gating mutations, including Class IV 
R117H mutations and Class II F508del mutations.22,25,57 However, with over 2000 mutations for 
CF, the use of CFTR modulators is still limited only to select CF patients, preventing widespread 
use of this treatment strategy.25   
1.2.2 Hypertonic saline and mucolytic agents 
Dehydration of the ASL and impaired mucociliary clearance are major pathological 
features of CF. These characteristics lead to airway obstruction by accumulated thick mucus in the 
lungs, persistent colonization of pathogens, and inflammation. As such, one of the crucial 
components of a patient’s regular treatment plan involves therapies focused on reducing mucus 
accumulation. Hypertonic saline is one of the most common therapies used to improve mucociliary 
12 
 
clearance by rehydrating the ASL.25 Inhalation of a sterile salt solution (typically ~3-7% NaCl) 
increases water content in the ASL and surface hydration.57–61 Increased hydration improves the 
clearance of stagnant mucus, enhancing overall lung function for CF patients.62  This treatment 
necessitates daily administration and is a part of a patient’s regimen.25,61 
Mucolytic therapies are also used to improve mucociliary clearance through breakdown of 
the mucus gel structure, thereby decreasing mucus viscoelasticity.63 Dornase alfa (trade name 
Pulmozyme) is currently the only FDA-approved mucolytic agent in use for the treatment of 
CF.25,57,63,64 Composed of recombinant human deoxyribonuclease I (rhDNase I), dornase alfa 
cleaves DNA released by disintegrated neutrophils in CF respiratory secretions. Treatment is 
administered via nebulization once daily, and a study consisting of over 3,000 patients has shown 
great improvement in patient health.65 Currently, dornase alfa is a highly effective mucolytic agent 
and one of the most successful CF therapeutics to date.25  
An alternative mucolytic agent garnering attention as a potential CF therapeutic is N-
acetylcysteine (NAC).  Inhalation of NAC is believed to reduce mucus viscoelasticity through the 
reduction of disulfide bonds within mucin glycoproteins, that replace disulfides with sulfhydryl 
moieties.63 Many in vitro studies have demonstrated the ability of NAC to reduce the viscosity of 
mucin solutions;57,66 however, no data currently supports the clinical efficacy of oral or aerosolized 
formulations of NAC.63,67 As a major obstacle for greater use, NAC has been shown to be 
incompatible with the aminoglycoside class of antibiotics (e.g., tobramycin).63,68 Therefore, NAC 
is currently not recommended for the treatment of CF but motivates further research toward the 




1.2.3 Antibiotics   
With chronic airway infections as the leading cause of patient mortality in CF, long-term 
antibiotic use has become a cornerstone for the treatment of the disease.10,70 Current approaches to 
eradicate the spectrum of CF-relevant bacteria include cycling through different classes of 
antibiotics to treat specific pathogens (e.g., P. aeruginosa, S. aureus). With Gram-positive bacteria 
highly prevalent in pediatric cases, anti-staphylococcal drugs (e.g., flucloxacillin) are commonly 
used during the early phase of CF.12,35 During adulthood, P. aeurginosa eradication is the principal 
focus of CF treatment. Indeed, anti-pseudomonal drugs (e.g., tobramycin, colistin, aztreonam 
lysine) are employed to treat infections.12,25 Inhalation of tobramycin, a U.S. FDA approved 
aerosolized aminoglycoside, is typically administered by nebulization twice daily at doses of 300 
mg.12,23,65,69 While the use of this antibiotic is the most recommended single strategy for P. 
aeruginosa managing bacterial infections, combination with other antibiotics (either delivered 
orally, intravenously, or via inhalation) is a standard regimen for patients with chronic P. 
aeruginosa infections.12,25  
The primary setback of persistent bacterial infection and the heavy use of antibiotics is the 
development of antibiotic resistance.71 The increased prevalence of multidrug-resistant (MDR) 
pathogens over the last decade, including MDR P. aeruginosa and MRSA, has raised concerns 
over the effective management of infection in CF.12,71 Moreover, the formation of bacterial 
biofilms poses significant challenges to the management of bacterial infections (Figure 1.5).6,9  The 
development of alternative dosages and methods for delivering different classes of antibiotics (i.e., 
aminoglycosides, β-lactams, macrolides) have become the main focus of recent research over 
designing next generation antibacterial treatments.12 The use of nano- and microparticle-based 












Figure 1.5 Biofilm-based bacterial colonization in the CF airways. Accumulation of a thick, 
stagnant mucus layer obstructs the airways and provides a suitable environment for biofilm-
based bacterial colonization. Both mucus and the biofilm exopolysaccharide matrix provide 
additional protection by limiting drug. In addition, slower growth rate and the different biofilm 
microenvironments reduce efficacy of antibiotics against biofilm-based infections. 
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of antibacterial agents. These systems improve diffusion through the viscous mucus layer by 
decreasing interactions with mucin glycoproteins, allowing for greater localized antibiotic 
concentrations and thereby lower overall required antibiotic doses. Studies using targeted drug 
delivery scaffolds (e.g., liposomes, PLGA microparticles) have demonstrated improved 
antibacterial efficacy over conventional, molecular antibiotics against common CF pathogens.72–
76 Despite promising results, innovations in pulmonary delivery still only represent a short-term 
solution to a broadening problem of antimicrobial resistance. An urgent need remains and 
necessitates the expansion of research on non-traditional antibacterial agents that can eradicate 
biofilm-based bacteria. 
1.2.4 Anti-inflammatory agents 
A persistent and excessive innate inflammatory response as a result of high bacterial burden 
ultimately causes lung degradation. Chronic inflammation warrants the use of anti-inflammatory 
therapeutics to mitigate decline in patient lung function and improve survival. Currently, ibuprofen 
is the only anti-inflammatory agent recommended for long-term treatment of CF airway 
inflammation.51,53,77 Therapies with corticosteroids have also been explored to treat inflammation, 
but serious, undesirable side-effects (e.g., weight loss, increased use of insulin) have limited their 
utility.46,51,53 Additionally, controlled trials have demonstrated no change in lung function between 
those treated with corticosteroids versus placebo.78    
1.2.5 Lung transplantation 
Lung transplantation is seen as a last-resort option for CF patients with advanced lung 
disease. As of 2015, the five-year survival rate for lung transplant patients with CF was about 67 
%.79 The survival rate for adults is generally much better compared to children.46  The majority of 
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CF transplant patient population is typically 30 or above, with only 6.2 % of CF-related lung 
transplants performed on patients younger than 18 years of age.22 However, lung transplantation 
is not a permanent cure for CF and only offers a chance of improvement to the patient’s health and 
quality of life. In addition to the risks associated with the surgical procedure and the possibility of 
organ rejection, immunosuppression is a major concern, with infection as a leading cause of patient 
mortality. Post-transplantation, the use of immunosuppressive drugs leave patients vulnerable to a 
host of invading pathogens.44,46,80  As such, lung transplants must be contemplated carefully on a 
case-by-case basis with consideration of associated risks, quality of life, and patient mortality. 
 
1.3 Nitric oxide as a potential CF therapeutic 
Nitric oxide (NO) is an endogenous, highly reactive free radical involved in the regulation 
of several physiological processes, including angiogenesis, vasodilation, neurotransmission, 
wound healing, and the immune response.81–89 The multifaceted roles involving NO has led 
researchers to investigate its use as a potential therapy for various diseases. In particular, NO’s 
role in the immune response to pathogens has sparked interest in the development of NO-based 
antibacterial therapeutics. As chronic bacterial infections are a central consideration in designing 
new CF therapies, this section examines the physiological roles of NO with a particular focus on 
its antibacterial action. Special attention is also given to recent studies that utilize exogenous NO 
as a CF therapeutic. 
1.3.1 Physiological roles of nitric oxide  
In the body, NO is an enzymatic product from the oxidation of L-arginine to L-citrulline 
via endothelial NO synthase (eNOS), neuronal  NOS (nNOS), or inducible NOS (iNOS).82–85 The 
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three isoforms catalyze the same reaction, but differ in terms of NO concentration produced, 
targets, and duration of NO production.82,85 The constitutive isoforms, eNOS and nNOS, produce 
low concentrations (pM-nM) of NO that act in regulatory and signaling functions. In the 
cardiovascular system, for example, NO produced by eNOS maintains vascular tone and 
myocardial contractility, regulates proper blood flow and pressure, and promotes antithrombotic 
effects.82 Deficiencies in NO due to endothelial injury can cause cardiovascular pathologies 
including antherosclerosis, arterial thrombotic disorders, coronary heart disease, hypertension, and 
stroke.81,82 Likewise, NO produced by nNOS acts as a neurotransmitter in the central nervous 
system, regulating the firing of neurons in the brain, membrane depolarization, and the release of 
neurotransmitters (e.g., serotonin, acetylcholine).85,86 In endothelial, epithelial, and inflammatory 
cells (e.g., macrophages and neutrophils), larger concentrations (µM) of NO are produced by iNOS 
as part of the host response against invading pathogens.83,85 Nitric oxide’s role in the immune 
system is of great interest in the development of novel antibacterial therapeutics. 
1.3.2 Nitric oxide as an antimicrobial agent 
Nitric oxide’s role as an antimicrobial agent is used by the innate immune response 
following exposure to foreign pathogens. Nitric oxide is produced via iNOS by proinflammatory 
cytokines and microbial byproducts (e.g., interleukins, lipopolysaccharides).90,91 Nitric oxide 
exerts both nitrosative and oxidative stresses on invading pathogens through the formation of 
reactive intermediates as shown in Figure 1.6.92–94 Nitrosative species, such as dinitrogen trioxide 
(N2O3), deaminates DNA and nitrosates thiols on microbial proteins.
81,94,95 Meanwhile, the 
reaction of NO with superoxide results in the formation of  peroxynitrite (ONOO-), causing the 
oxidative destruction of DNA and protein structures as well as membrane damage via lipid 










Figure 1.6 The multi-mechanistic pathways of NO’s antibacterial activity. Nitrosative and 
oxidative stress is exerted by reactive byproducts such as dinitrogen trioxide (N2O3) and 
peroxynitrite (ONOO-). Reprinted with permission from Hetrick et al. Copyright 2008, 
American Chemical Society. 
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spectrum activity against nearly all pathogens, including both Gram-positive and Gram-negative 
bacteria.81,97 Moreover, the multiple molecular targets of NO’s antimicrobial activity make it 
unlikely for bacteria to develop resistance to NO. Indeed, a study by Privett et al. demonstrated 
that exposure to exogenous NO resulted in a negligible increase in the required inhibitory NO 
concentration for planktonic species of different bacterial species, including antibiotic-resistant 
strains, even after several passages (20 d).98 
In addition to broad-spectrum antibacterial activity against planktonic bacteria, NO also 
exhibits a dose-dependent effect against bacterial biofilms.93,99,100 After biofilm maturation, the 
dispersal of planktonic bacteria from biofilms is essential for limiting overcrowding of bacteria 
within the EPS matrix. This purpose also allows for further colonization.101 Biofilm dispersal 
occurs in three phases: i) detachment of planktonic cells from the mature biofilm, ii) translocation 
of these planktonic cells, and iii) attachment of planktonic cells to a new substrate. Arora et al. 
previously reported that NO acts as a signaling molecule to mediate biofilm dispersal at low 
concentrations (pM-nM).100 While the mechanism describing or controlling NO’s ability to trigger 
biofilm dispersal remains unclear, a popular hypothesis involves NO’s ligation to the cyclic 
diguanylate (cGMP) signaling molecule, which is involved in the production and maintenance of 
the biofilm EPS matrix.100,102 By initiating biofilm dispersal, NO can be utilized to increase 
bacterial susceptibility to common antibacterial agents.92,93 Barraud et al. reported the pretreatment 
of P. aeruginosa biofilms with sub-eradication concentrations of a low molecular weight NO 
donor (500 nM for 24 h). This NO pretreatment resulted in enhanced biofilm  susceptibility to 
multiple antibacterial agents (e.g., tobramycin, hydrogen peroxide), allowing for a 2-log reduction 
in bacterial viability compared to biofilms treated with test agents alone.92 
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At higher concentrations (µM-mM), complete biofilm eradication is achieved.93,103 
Although the exact mechanism of NO-mediated biofilm eradication is still unknown, destruction 
of the biofilm EPS matrix is likely to be a  main factor.104,105 Within the same concentration range, 
NO is capable of exerting bactericidal activity, further supporting NO’s role in biofilm eradication. 
A recent study by Neufeld and Reynolds, for example, demonstrated that NO delivered by a low 
molecular weight donor (1.5 mM NO) was able to decrease the bacterial viability of P. aeruginosa 
biofilms by >1-log after a 12 h exposure.103 As such, the development of materials that are capable 
of storing and releasing large (~µM) NO concentrations is of great interest for biofilm eradication. 
1.3.3 Nitric oxide in CF therapy 
The utility of exogenous NO as a CF therapeutic has become appealing due to its broad-
spectrum antibacterial activity.92,93,106–110 Two main approaches have been investigated for NO-
based therapy including the supplementation of L-arginine, NO’s biological precursor, and the 
direct inhalation of NO gas.111–115 Production of NO is increased in airways diseases with chronic 
inflammation and bacterial infection (e.g., asthma, COPD). However, the opposite is true for CF, 
where exhaled NO levels are dramatically lower compared to healthy individuals.116 As such, 
decreased levels of exhaled NO have been correlated with poor pulmonary health in CF 
patients.116–118 One hypothesis suggests that NO is scavenged by proteins and reactive oxygen 
species (ROS) in mucus.116,117 The thick, viscous mucus layer prevents the diffusion of NO and 
converts it into stable metabolites (e.g., nitrate, nitrite, and nitrotyrosine).116,117 Further, the 
consumption of NO by pathogens (e.g., P. aeruginosa) during anaerobic metabolism is believed 
to reduce exhaled NO levels.118 Additionally, it is hypothesized that available concentrations of L-
arginine are diminished, thereby decreasing NO production.119,120 Oral, intravenous, and inhaled 
administration of L-arginine have been proposed as solutions for this deficiency.113–115,121 Of the 
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different routes of administration, the inhalation of nebulized L-arginine solutions has been found 
to be most effective. Grasemann and coworkers reported an increase in exhaled NO levels and 
improved pulmonary function, as characterized by forced air expiratory volume in 1 second 
(FEV1) from CF patients following single dose treatments of nebulized L-arginine (7 wt% L-
arginine hydrochloride solution).115 In a follow-on study, it was shown that twice daily L-arginine 
inhalation for two weeks improved exhaled NO levels compared to inhalation of a saline solution 
over the same treatment period.114 Of note, no improvement in FEV1 levels were observed over 
the extended exposure period. Altogether, these studies suggest that L-arginine supplementation is 
a viable therapeutic to increase exhaled NO levels in CF patients. However, no evidence exists to 
suggest that this treatment strategy improves pulmonary function for extended periods. 
 As an alternative therapy, the antibacterial efficacy of directly inhaled gaseous NO has 
been investigated.106–109 Webert et al. reported a significant reduction in P. aeruginosa 
colonization in intratracheally injected rats after inhalation of NO gas (40 ppm in air, 24 h, 
continuous administration).108 Unfortunately, increasing the length of exposure to 48 h resulted in 
rat mortality, suggesting that sustained high NO doses are problematic. Jean and coworkers 
examined the efficacy of lower doses of NO gas (10 ppm in oxygen, 24 h continuous 
administration).109 At the lower doses tested, NO gas was only effective at reducing bacterial load 
when mixed with pure oxygen instead of room air, but this also resulted in an increase in airway 
inflammation. Miller et al. attempted to improve the bactericidal efficacy of gaseous NO while 
simultaneously reducing toxicity with the use of intermittent administration of higher NO doses 
(160 ppm in air, 30 min treatments every 4 h).106 This periodic treatment method decreased the 
bacterial load of P. aeruginosa in rat lungs. In a more representative study, intermittent treatment 
with NO gas was administered to eight CF patients.110 Results showed both improved lung function 
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(increased FEV1 in patients) and a significant reduction in the bacterial load of multiple microbial 
pathogens, including P. aeruginosa, S. aureus, and Mycobacterium abscessus. 
 In addition to antibacterial applications, inhalation of gaseous NO has been proposed as a 
mucolytic therapy.122 Thoroughbred horses with mucus hypersecretion in the airways were 
subjected to multiple treatment cycles of NO gas (100 breaths, 5,000-10,000 ppm) over several 
weeks. The treatments resulted in decreased mucus accumulation in the airways and facilitated 
clearance of non-viscous fluids from the nostrils. While the efficacy of gaseous NO regarding its 
mucolytic activity was demonstrated in the study, the mechanism by which NO elicits this response 
has not been systematically characterized. One hypothesis suggests that NO cleaves mucin 
glycoproteins through S-nitrosation of its cysteine residues.122,123 Another idea proposes the 
depolymerization of O-linked polysaccharides in the glycosated domains of the glycoprotein to 
alter intra-mucin interactions.104 Nitric oxide may also cleave DNA in CF mucus to reduce its 
viscoelastic properties.105 Still, factors (e.g., NO dose, delivery method) affecting NO’s mucolytic 
activity and the mechanism by which NO exerts mucolysis remain unclear. 
To date, treatments with gaseous NO have demonstrated NO’s potential as a dual-action 
therapeutic that targets both chronic bacterial infection and mucus accumulation in the airways. 
However, the therapeutic utility of inhaled NO gas is limited by the hazards associated with the 
use of pressurized cylinders, rapid scavenging of NO in biological media, and toxicity concerns 
with continuous use at high concentrations.124 The need for novel systems designed specifically 





1.4 Nitric oxide delivery  
An alternative to direct inhalation of gaseous NO is the use of donor molecules capable of 
stable storage and controlled delivery of NO. Several classes of NO donor systems exist, including 
N-diazeniumdiolates, S-nitrosothiols (RSNOs), organic nitrates, and metal nitrosyls.124 A wide 
variety of macromolecular NO donor scaffolds, including dendrimers,125–130 silica 
nanoparticles,94,131–135 and chitosan,136–138 have also been specifically designed for NO delivery for 
several biomedical applications.81,97,139,140 However, not all scaffolds are suitable for delivery of 
NO to the airways due to scaffold toxicity concerns (e.g., dendrimer secondary amine toxicity), 
poor water solubility, and ineffective clearance from the lungs. Thus, a more compatible scaffold 
must be developed for efficient pulmonary NO delivery. 
1.4.1 Small molecule nitric oxide donors  
Of the multiple classes of NO donors, RSNOs and N-diazeniumdiolates have garnered the 
most interest due to their ability to spontaneously release NO in biological media. S-nitrosothiols 
(e.g., glutathione, nitrosoalbumin) are a class of NO donors that serve as endogenous NO delivery 
systems.124,141 In exogenous preparations, RSNOs are created via the nitrosation of thiols with a 
nitrosating agent (e.g., nitrous acid, nitrites, nitrogen oxides) under acidic conditions.97,124,142 Nitric 
oxide release from the RSNO is triggered through multiple decomposition pathways (Figure 1.7A), 
each involving the homolytic cleavage of the S─NO bond.124,142,143 Photo and thermal 
decomposition both result in the formation of a thiyl radical along with the liberation of NO. The 
thiyl radical can react with another RSNO to yield an additional mole of NO and a disulfide. In 
the airways, NO release from RSNOs occurs through either thermal decomposition or via reaction 
with endogenous ascorbic acid, which acts as a reducing agent.144 Ascorbic acid depletion, 












RSNOs.145 The utility of RSNO-based therapies is thus limited for CF applications necessitating 
an alternative donor system. 
A more suitable NO donor for the development of NO-based CF therapies are N-
diazeniumdiolates. These donors are prepared via exposure of secondary amine functional groups 
to high pressures of NO gas under basic conditions (Figure 1.7B).124 Proton-mediated 
decomposition then yields two moles of released NO and the corresponding precursor amine 
molecule.124,146 In addition to temperature and pH, the stability and NO-release kinetics of N-
diazeniumdiolates are directly affected by the precursor amine structure.124,147,148 Nitric oxide-
release half-lives under physiological conditions for small or low molecular weight donors 
typically range from 2 s for cation-stabilized N-diazeniumdiolate-modified proline (PROLI/NO) 
to 20 h for amine-terminated NO-releasing diethylenetriamine (DETA/NO).147,148 In the case of 
DETA/NO, increased stabilization of the N-diazeniumdiolate moiety through hydrogen bonding 
from the terminal primary amine results in the extended NO-release profile.147–150 As such, N-
diazeniumdiolates are a versatile NO donor system with tunable release properties. 
1.4.2 Macromolecular scaffolds for nitric oxide delivery 
While many initial studies have focused on developing small molecule NO donors for the 
controlled storage and release of exogenous NO as an alternative to gaseous NO, the therapeutic 
utility of these systems is limited by untargeted NO delivery and precursor toxicity 
concerns.81,124,146 These problems have been addressed through the development of 
macromolecular NO donor systems.97,124,139,140 Modification of macromolecules with NO donors 
allows for improved localization of NO-release and reduced cytotoxicity. Likewise, the use of 
macromolecular NO delivery systems enhance NO’s efficacy due to potential targeting 
mechanisms (e.g., incorporation of functional groups that can interact and penetrate the bacterial 
26 
 
wall) and unique NO payloads.124,139 Much research has thus focused on the design of NO-
releasing macromolecules, including inorganic nanoparticles (e.g, gold, silica), synthetic polymers 
(e.g., dendrimers), and biopolymers (e.g., chitosan), for a range of biomedical 
applications.81,97,139,140  
 
1.5 The ideal NO-releasing scaffold for CF delivery 
Nitric oxide holds potential as a dual-action (i.e., antibacterial and mucolytic) treatment for 
CF. To successfully administer exogenous NO using macromolecular structures, certain properties 
of the delivery scaffold must be taken into consideration. First and foremost, the scaffold must be 
highly water soluble to allow for direct inhalation of the NO-based treatment into the airways via 
nebulization. Molecular weight, charge, and functional moieties each influence the water solubility 
of macromolecules. The same factors also affect other properties desired for an ideal CF therapy, 
such as its ability to penetrate and release active agents through the highly viscoelastic airway 
mucus. Both the overall charge and molecular weight dictate a scaffold’s ability to electrostatically 
interact or entangle with the components of the mucus layer. Neutral and negatively charged 
materials (e.g., poly(ethylene glycol), polylactic-co-glycolic acid, alginate) are found to be 
advantageous for pulmonary drug delivery due to improved penetration through the mucus layer, 
minimizing interactions with mucin glycoproteins, for example.12,151–156 Positively charged 
polymers such as chitosan have also garnered great interest for the treatment of bacterial infections 
in CF patients, as their charge allows for improved localization (e.g., attachment on mucus layer 
surface) of the administered antibacterial agent.12,75,157–161 In this regard, the properties (or the 
identity) of the biopolymer can influence the efficacy of drug delivery. It may even impact the 
mucus viscoelasticity with the scaffold’s interactions with its components.  
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The efficacy of NO-based antibacterial agents is also dependent on macromolecule scaffold 
properties (e.g., size, shape, charge, water solubility) and the associated NO release (e.g., half-
lives and total NO payloads).129,130,135,162,163 Lu et al. synthesized NO-releasing silica nanorods 
(SNRs) with diverse NO-release kinetics and particle morphologies.162  Antibacterial activity of 
the NO-releasing SNRs were dependent on both the NO-release properties and particle 
morphology, with a larger NO flux (i.e., instantaneous amount of NO released) and higher aspect 
ratio (i.e., ratio of  length to width of the particle) resulting in more bactericidal action. In a similar 
study, Slomberg et al., reported on the antibiofilm efficacy of NO-releasing silica particles of 
different sizes (i.e., 14, 50, and 150 nm) and shapes (i.e., rod-like vs. spherical particles) against 
P. aeruginosa and S. aureus biofilms.135 Treatment with 14 nm NO-releasing silica particles 
resulted in enhanced bactericidal activity compared to larger particles (50 and 150 nm), the former 
allowing for better particle diffusion through the biofilm. Regarding particle shape, rod-like NO-
releasing particles were found to have greater antibacterial action compared to spherical particles. 
The rod-like particles allowed for improved diffusion and greater contact area between the particle 
and the bacterial membrane, resulting in greater NO delivery (dose). 
For dendrimers, Sun et al. demonstrated the antibacterial efficacy of NO-releasing 
poly(propyleneimine) (PPI) systems against planktonic forms of P. aeruginosa and S. aureus.129 
The bactericidal action was reported to be dependent on dendrimer generation (i.e., size), exterior 
functional groups, and NO-release properties. Dendrimers with hydrophobic terminal groups 
allowed for increased association with the hydrophobic bacterial cell membrane. On the other 
hand, larger sizes (i.e., higher generations) allowed for increased functional group density, 
resulting in greater intercalation with the bacterial cell wall and more efficient NO delivery. 
Similarly, Lu et al. reported the synthesis of NO-releasing amphiphilic poly(amidoamine) 
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(PAMAM) dendrimers with enhanced bactericidal activity against both planktonic and biofilm 
forms of P. aeruginosa.130 The antibacterial efficacy was dependent on both the identity of the 
hydrophobic exterior modification and dendrimer generation. While higher dendrimer generations 
appear to be a desirable feature for enhanced bactericidal action, cytotoxicity was also noted 
against mammalian cells at the concentrations necessary to achieve biofilm eradication.  
For the development of CF therapeutics, the nebulization of water-soluble NO-releasing 
macromolecular scaffolds that are biocompatible and capable of sustained NO release may 
represent an attractive strategy for pulmonary NO delivery. Of the various systems potentially 
available, biopolymers (e.g., chitosan, dextran, alginate) hold the greatest promise due to their 
biocompatibility and low toxicity, high functionality, and water solubility.97   
1.5.1 Initial work with nitric oxide-releasing chitosan oligosaccharide 
Chitosan is one of the most extensively studied NO-releasing biopolymeric systems to date. 
Lu et al. first reported on the synthesis of highly water soluble N-diazeniumdiolate-modified 
chitosan oligosaccharides.137 By tuning the ratio of 2-methylaziridine grafted onto the chitosan 
oligosaccharides (COS), a range of secondary amine concentrations and resulting NO payloads 
(i.e., 0.3-0.8 µmol/mg) were obtained. These NO-releasing chitosan biopolymers (COS/NO) 
exhibited antibacterial action against both planktonic and biofilm forms of P. aeruginosa. Neither 
control (non-NO-releasing) nor the NO-releasing COS elicited toxicity against mammalian cells 
at their concentrations required to achieve bactericidal activity. 
Reighard et al. evaluated the antibacterial efficacy of NO-releasing chitosan 
oligosaccharides in the absence and presence of oxygen using nonmucoid, mucoid, and biofilm P. 
aeruginosa phenotypes. It was demonstrated that NO treatment under low oxygen environments 
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resulted in more effective killing relative to tobramycin, the current standard of care for treating 
CF infections.164 In a follow-up study, NO’s ability to degrade P. aeruginosa biofilms was 
evaluated using chitosan oligosaccharides with optimized NO-storage capabilities.165 Treatment 
with COS/NO resulted in the disruption of the structural integrity of the biofilm EPS. Reighard et 
al. also reported on NO’s potential utility as a mucolytic agent.166 Modification with ester 
functional groups reduced the overall charge of the biopolymer and mitigated chitosan’s inherent 
mucoadhesivity (i.e., ability of the biopolymer to adhere to mucus). Secondary amine-modified 
COS without ester functional groups demonstrated the greatest efficacy at reducing CF sputum’s 
viscoelasticity. The cationic nature of the COS backbone resulted in the aggregation of mucin in 
sputum samples, while NO release from COS/NO allowed for the degradation of the mucin 
network. Overall, these studies demonstrate the potential efficacy of positively charged 
biopolymers for delivering NO for CF applications. 
1.5.2 Limitations of chitosan oligosaccharides for NO delivery in CF 
While NO’s potential utility as a dual-action therapeutic agent holds great promise, the 
initial studies with chitosan lack a systematic evaluation of how molecular weight, charge, and 
NO-release properties might influence NO’s action. Chitosan is only water soluble up to 10 kDa, 
limiting the molecular weight range that can be studied.137,167 While the NO-releasing biopolymer 
exhibited a dose-dependent action with biofilm degradation, control chitosan oligosaccharides 
actually increased biofilm elasticity, suggesting that the non-NO-releasing scaffold may limit 
NO’s efficacy – a potential drawback of using a cationic biopolymer.165 Further functionalization 
of the primary amine terminal group of COS with acrylates did not significantly alter the 
biopolymer’s NO-release properties, restricting the scope of the previous study.166 To fully 
elucidate the impact of both NO release and scaffold properties (i.e., molecular weight and charge), 
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expanding the work originally performed with NO-releasing chitosan oligosaccharides using 
anionic or neutral biopolymers with potential for diverse NO-release properties is warranted. 
 
1.6 Alginate in the treatment of cystic fibrosis 
Alginate represents an ideal NO donor biopolymer for use in the CF lung due to its 
biocompatibility, low toxicity, and water solubility.168,169 The hydroxyl and carboxylic acid 
functional groups of alginate offer sites for straightforward chemical modification. For these 
reasons, the development of alginate-based therapies has generated great interest across numerous 
biomedical applications, including wound dressings,169–171 drug delivery,172–174 potentiators for 
antimicrobial agents,175–177 and more recently, as mucin modifiers for cystic fibrosis.151–154 The 
development of a dual-action antibacterial and mucolytic NO-based therapy using alginate 
biopolymers is certainly conceivable and potentially attractive. 
1.6.1 Alginate as a potential scaffold for NO delivery 
As shown in Figure 1.8, alginate is an anionic polysaccharide composed of 1,4-linked β-D-
mannuronic acid (M) and α-L-guluronic acid (G) residues.173 Commercially available alginates are 
typically derived from brown algae (Phaeophyceae), including Laminaria hyperborean, 
Ascophyllum nodosum, and Macrocystis pyrifera.172,173 Alginate may also be extracted from 
bacteria including Azotobacter vinelandii and Pseduomonas species.172,173 The composition and 
residue sequence depend on the source from which the alginate is isolated.172 Alginate rich in G 
residues are prepared from stripes of old L. hyperborean kelp,.172,173 whereas alginate with up to 
100% M residues are often isolated from Pseudomonas strains.172,178  
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Alginate’s molecular weight and composition (i.e., M/G sequence) dictate its viscosity in 
solution. Commercially available alginates have molecular weights ranging from 32 to 400 kDa.173  
Higher molecular weight alginates (≥100 kDa) containing a high G (≥70%) content form hydrogels 
with enhanced mechanical properties and high stiffness compared to those having decreased G 
content (≤30%).173,179,180 The G monomeric units adopt a buckled conformation while the M 
monomers take the shape of an extended ribbon (Figure 1.8).181 Neighboring G monomers form 
diamond-shaped holes that are capable of cooperative binding with multivalent cations (e.g,, Ca2+), 
causing gellation.172,173,178,179,181 Increasing the G density of alginate has been reported to increase 
selective binding to alkaline metal ions (e.g., preferential binding with Ca2+ compared to Mg2+), 
whereas M-rich residues and alternating blocks of G and M monomers exhibit relatively low ion 
selectivity.169,182  Alginate undergoes pH-dependent hydrolysis to form “alginic gels” as a result 
of interactions between the protonated homopolymeric sequences (i.e., repeating units of the same 
monomer).172,174,180,183 Similar to gelation via ionic crosslinking, G monomer residues appear to 
be most effective for junction formation within the gels, producing gels with high stiffness.180,183 
In addition to affecting physical morphology, the overall composition of alginate also 
affects its biocompatibility and antigenicity.172,173 For example, alginate with high G content has 
been shown to elicit a mild immunological response, while M residue rich alginate was more 
immunogenic. Alginate with high M content induces cytokine production up to 10-fold greater 
than G-rich alginate.173,184 The alginate backbone offers the ability for straightforward chemical  
modification at hydroxyl and carboxylic acid functional groups, imparting unique versatility with 
respect to drug storage and release, and control over solubility, biocompatibility, as well as 
degradation rates.169,173 Alginate is also approved for use by the U.S. Food and Drug 














Figure 1.8 Alginate polysaccharide composed of α-L-guluronic acid (G) and β-D-mannuronic 
acid (M) residues. 
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additives and have become important biopolymers for a wide range of biomedical applications 
(e.g., raft-forming formulations for the treatment of heartburn and gastric reflux, protein and cell 
delivery vehicles in tissue regeneration, and dressings for the treatment of acute and chronic 
wounds).169,179  
1.6.2 Alginate in antibacterial applications  
The unique properties of alginate (e.g., water solubility at high molecular weights) make it 
an excellent scaffold for the delivery of antibacterial agents (e.g., silver and zinc). Traditional use 
of alginate as a non-woven dressing has sparked interest in developing alginate-based materials 
imbued with antibacterial properties for wound-healing applications. In a study by Hajial et al., 
sodium alginate polyethylene oxide nanofibers containing lavender oil (SA-PEO/LO; 5% v/v 
lavender oil) were used to treat skin burns (induced by midrange ultraviolet radiation) on rats.185  
Bactericidal efficacy was evaluated using S. aureus, a common pathogen found in burn wounds. 
The nanofibers were shown to inhibit growth of S. aureus colonies, creating inhibition zones of 
~20 mm after 24 h of treatment. In vitro studies showed that the nanofibers were biocompatible, 
and that both SA-PEO/LO and control SA-PEO nanofibers demonstrated strong anti-inflammatory 
action, as evidenced by reduced pro-inflammatory cytokine counts. In vivo studies also revealed 
the ability of these materials to promote wound healing from burn injuries, showing no evident 
burn marks on the skin of mice treated with control PEO nanofiber dressings. Yang et al. developed 
nano-silver/sodium alginate (Ag/SA) composite nanoparticles that showed superior antibacterial 
activity towards E. coli and S. aureus (MIC values of 0.25 and 0.13 µg/mL, respectively) compared 
to previously reported silver nanoparticles (0.78-6.25 µg/mL) and pluronic-coated silver 
nanoprisms (24 µg/mL) following a 24-h exposure.186–188 The Ag/SA particles demonstrated 
antibacterial activity against both pathogens after 30 d of exposure to the fiber (MIC of 0.51 µg/mL 
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for E.coli and 0.26 µg/mL for S. aureus). Cloth fabrics submerged in a solution of Ag/SA 
nanoparticles also exhibited antibacterial properties against colonies of S. aureus, with inhibition 
zone diameters improving (1.8-4.8 mm) with increasing concentrations of silver nanoparticles 
(0.16-0.57 mg/mL).186 Overall, these studies demonstrate the promise of alginate used in in the 
delivery of antibacterial agents.  
1.6.3 Alginate as a potentiator for antimicrobial activity 
Current studies highlight alginate’s use as a potentiator for antibiotics (e.g. collistin, 
aztreonam, erythromycin) and as a biofilm dispersant.175–177 Khan et. al reported on the use of low 
molecular weight alginate oligosaccharides (OligoG, 2.6 kDa) to treat multi-drug-resistant 
bacteria, including different strains of Pseudomonas, Acinetobbacter, Burkholderia species, and 
MRSA.176 Addition of OligoG to liquid cultures reduced bacterial proliferation in a dose-
dependent manner, showing a general decrease in percent change in the cell density with respect 
to control. This effect was particularly evident in the Gram-negative pathogens tested. Imaging 
PAO1 P. aeruginosa biofilms revealed disruption of established biofilms, increased cell death, and 
decreased cellular density with increasing concentrations (0 to 10%) of OligoG. Treatment with 
OligoG also improved the efficacy of a range of antibiotics, including macrolides (e.g., 
azithromycin) by up to 512-fold against Gram-negative MDR pathogens. A similar effect was 
observed in Gram-positive species, albeit to a lesser extent.  
In a subsequent study, the efficacy of OligoG was evaluated against oral biofilms (i.e., P. 
gingivalis and S. mutans). Pre-treatment of titanium and polymethlmethacrylate (PMMA) discs 
with triclosan did not inhibit bacterial attachment. In contrast, triclosan in combination with 
OligoG resulted in a significant decrease in biofilm attachment for P. gingivalis. Bacterial imaging 
studies with P. gingivalis biofilms exposed to high concentrations of OligoG (≥ 6%) revealed a 
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decrease in cell numbers and increased numbers of non-viable cells. Atomic force microscopy 
(AFM) studies also revealed that treatment with OligoG resulted in both structural and cellular 
changes. Similarly, exposure to the same concentrations of OligoG altered S. mutans biofilm 
morphology, producing obvious cellular aggregation and clumping in biofilms and new pores that 
might improve diffusion of antibacterial agents.175   
Hengzhuang and coworkers recently reported the effect of OligoG treatment in an in vivo 
murine lung infection model. Biofilm disruption after a 24-h treatment period with OligoG proved 
dose-dependent, with up to 2.5-log reduction in bacterial viability of P. aeruginosa in infected 
mouse lungs. In vitro assays with OligoG also reduced the required colistin concentrations (512 
µg/mL to 8 µg/mL) required to eradicate biofilms after an 8-h exposure.177 As demonstrated by 
the above studies, low molecular weight alginate oligosaccharides have utility as potentiators of 
antibacterial and biofilm dispersal agents. 
1.6.4 Alginate as a mucomodulator 
The ability of alginate to alter mucus rheology is also an active area of research. Alginate 
oligosaccharides rich in G units have been shown to decrease both mucus viscosity and elasticity 
by inhibiting interpolymer crosslinking and intramolecular interactions between mucin 
glycoproteins.151,152 Nordgård and coworkers reported that treatment with alginate 
oligosaccharides decreased the viscoelastic properties of mucin gels as well as mucin-DNA gels.153  
Subsequent studies have shown the ability of alginate oligosaccharides to create pores in the mucus 
network and alter matrix architecture.151,154 Treatment with alginate oligomers also led to increased 
particle diffusion through the mucus layer, indicating the potential for improved drug delivery in 
the airways. Recent work by Pritchard et al. also demonstrated that at 2 wt% concentration of 
OligoG managed to reduce the viscoelasticity of CF sputum with comparable efficacy to that of 
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rhDNAse I.151 Altogether, these studies clearly denote the benefits of developing alginate-based 
therapies for the treatment of CF, particularly for decreasing the viscoelasticity of mucus in the 
airways.   
 
1.7 Summary of dissertation research 
 The goal of my dissertation research was to design NO-releasing alginates as a dual-action 
mucolytic-antibacterial therapeutic for the future potential treatment of CF. My initial efforts 
involved first modifying alginate to store and release NO, followed by subsequent examination of 
NO-release properties. How these amine functional groups and NO-releasing moieties affected 
alginate’s ability to alter the rheological properties of mucus was then examined. Lastly, the 
antibiofilm efficacy of the NO-releasing alginates against different bacteria under CF-relevant 
conditions was also determined. In summary, the objectives of my dissertation research included:  
1. Synthesis of water-soluble high and low molecular weight alginates with tunable NO 
storage and release properties; 
2. Assessment of the mucolytic efficacy of the NO-releasing alginates on the bulk rheological 
properties of human bronchial epithelial (HBE) mucus; and, 
3. Evaluation of the antibacterial efficacy of the NO-releasing alginate derivatives against 
bacterial biofilm cultures of CF-relevant pathogens under conditions that mimic diseased 
airways. 
 In this chapter, the pathogenesis of CF, a review of current treatment methods for the 
disease, and the motivations for using NO-based therapeutics were fully described. In particular, 
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the benefits of designing an alginate-based NO delivery system were introduced. Chapter 2 
describes the synthesis of high and low molecular weight alginates functionalized with small 
molecule alkyl amines to produce anionic NO-releasing biopolymers. The effect of molecular 
weight and amine precursor structure on total NO storage, NO-release kinetics, toxicity, and 
antibacterial action under static conditions are discussed.  Chapter 3 examines how the physical 
properties (e.g., molecular weight, scaffold charge), NO-release properties, and concentration of 
the alginate systems affect mucus viscoelasticity. A comparison with a conventional mucolytic, 
NAC, was also carried out to assess the potential benefits of the NO-releasing biopolymer. Chapter 
4 demonstrates the use of NO-releasing alginate as a bactericidal agent against P. aeruginosa, 
BCC, S. aureus, and MRSA under CF-relevant conditions. In addition, NO release under 
biological conditions and the antibiofilm activity of the alginate systems compared to traditional 
antibiotics (e.g., tobramycin) were investigated. Lastly, Chapter 5 provides a summary of the 
dissertation work presented herein and suggests future directions for the evaluation and 
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CHAPTER 2: NITRIC OXIDE-RELEASING ALGINATES 
2.1 Introduction 
 Bacterial infections pose a great challenge to human health in community and hospital 
settings.1–3 Chronic infections associated with implanted devices,4 wounds,2,5 and cystic fibrosis4,6 
are frequently caused by biofilm-forming pathogens, including Pseudomonas aeruginosa and 
Staphylococcus aureus.4,7 Bacteria in biofilms are particularly challenging to address as they form 
an exopolysaccharide (EPS) matrix as a protective mechanism from the host immune response and 
antibiotic interventions. Indeed, eradication of bacteria in biofilms may require up to 1000 times 
greater antibiotic concentrations relative to those needed to kill planktonic bacteria.8 Several 
factors contribute to such protection, including slower bacterial metabolism, limited diffusion of 
the antibacterial agent (e.g., antibiotic) through the EPS matrix, and altered microenvironments 
(e.g., regions of nutrient or oxygen depletion).4,7,9 Furthermore, bacteria have developed potential 
cellular mechanisms (e.g., self-alteration of cell membrane targets and the use of pumps to reduce 
internal concentration of antibiotics) that minimize the effects of antibiotics. New antibacterial 
agents that can more effectively penetrate and effectively act on biofilm-based bacterial colonies 
are greatly needed in the fight against emerging antibiotic-resistant pathogens.10 
Nitric oxide (NO) is an endogenous free radical that plays an integral role in the innate 
immune response to foreign pathogens. Much of NO’s broad-spectrum antibacterial activity is 
accounted for by its reactive byproducts, including peroxynitrite and dinitrogen trioxide, which 
exert oxidative and nitrosative damage to microbial DNA and membrane structures.11–15 As a result 
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of NO’s small size and the mechanisms by which it exerts antibacterial action, bacteria are unlikely 
to foster resistance to NO.16 The hazards of pressurized cylinders, NO’s high reactivity in 
biological media, and even toxicity concerns have led researchers to develop and study the utility 
of NO donors – both small molecule and macromolecular systems – as a means for storing and 
releasing NO under specific environmental conditions.12,14,17 N-diazeniumdiolate NO donors have 
garnered much attention due to the spontaneous liberation of NO in aqueous solution at 
physiological pH.14 While NO’s role in immune cell response to pathogens is clear, developing 
therapies based on the delivery of NO gas is challenging. Unfortunately, NO payloads for small 
molecule NO donors can be limited with precursor toxicity risks when larger concentrations are 
required.17 To address such concerns, we have focused on the development of macromolecular N-
diazeniumdiolate NO-release systems with inherently superior NO payloads, control over NO 
release kinetics, and unique release mechanisms.18–24  
Biopolymers such as chitosan, cellulose, and alginate represent attractive potential NO 
donor scaffolds due to their inherent biodegradability and favorable toxicity profiles.25,26 Alginate, 
a naturally occurring anionic polymer consisting of 1,4-linked α-L-guluronic acid (G) and β-D-
mannuronic acid (M) units,25,27–30 is water soluble even at high molecular weights (>200 kDa), a 
critical property for in situ release.27,28 As a results of these properties, investigators have studied 
alginate’s utility for a number of biomedical applications including wound dressings,30–32 drug 
delivery,5,30,33 potentiators for antimicrobial agents,28 and mucin modifiers for cystic 
fibrosis.29,30,34,35 The alginate backbone offers straightforward chemical modification at hydroxyl 
and carboxylic acid functional groups, imparting unique versatility with respect to drug storage 
and release, and control over solubility, biocompatibility, and degradation rates.27,36,37 
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Herein, we describe the functionalization of both high and low molecular weight alginates 
with small molecule alkyl amines for subsequent modification with N-diazeniumdiolate NO 
donors to produce anionic NO-releasing biopolymers. The alkyl amine precursors were selected 
based on prior literature describing diverse NO-release kinetics related to breakdown of the N-
diazeniumdiolate.38,39 The bactericidal action of the alginates was examined with respect to NO-
release kinetics, total NO storage, amine precursor structure, and molecular weight.  
  
2.2 Experimental Section 
2.2.1 Materials 
 Alginic acid sodium salt from brown algae (low viscosity), bis(3-aminopropyl) amine 
(DPTA), diethylenetriamine (DETA), N-propyl-1,3-propanediamine (PAPA), spermine (SPER), 
phenazine methosulfate (PMS), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC), N-hydroxysuccinimide (NHS), trypsin, penicillin streptomycin (PS), 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt 
(MTS), were purchased from Sigma-Aldrich (St. Louis, MO). Roswell Park Memorial Institute 
(RPMI) 1640 cell culture medium and common laboratory salts and solvents were purchased from 
Fischer Scientific (Fair Lawn, NJ). Unless otherwise specified, all chemicals were used as received 
without further purification. Tryptic soy broth (TSB) and tryptic soy agar (TSA) were obtained 
from Becton, Dickinson, and Company (Franklin Lakes, NJ). Pseudomonas aeruginosa (P. 
aeruginosa; ATCC #19143), Staphylococcus aureus (S. aureus; ATCC #29213), and A549 human 
lung epithelial cells (ATCC CCL-185) were obtained from American Type Tissue Culture 
Collection (Manassas, VA). Argon (Ar), carbon dioxide (CO2), nitrogen (N2), nitric oxide (NO) 
calibration (25.87 ppm, balance N2) gas cylinders were purchased from Airgas National Welders 
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(Raleigh, NC). Pure NO gas (99.5%) was obtained from Praxair (Sanford, NC). Distilled water 
was purified to a resistivity of 18.2 Mꭥ.cm and a total organic content of ≤6 ppb using a Millipore 
Milli-Q UV Gradient A10 System (Bedford, MA). 
2.2.2 Instrumentation 
 1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker (600 
MHz) spectrometer. Elemental (carbon, hydrogen, and nitrogen; CHN) analysis was performed 
using a PerkinElmer Elemental Analyzer Series 2400 Instrument (Waltham, MA). Zeta potential 
measurements were collected in phosphate buffer (10 mM PB; pH 7.4) using a Zetasizer Nano 
(Malvern Instruments, UK). All absorbance measurements were made in 50 mM sodium 
hydroxide (NaOH) using a UV-vis Lambda 40 Spectrophotometer (PerkinElmer, Waltham, MA). 
Gel permeation chromatography measurements were carried out in 0.1 M sodium nitrate using an 
aqueous GPC-multi-angle light scattering system equipped with a Waters 2414 refractive index 
detector (Milford, MA) coupled to a Wyatt miniDawn TREOS multi-angle light scattering detector 
(Santa Barbara, CA).  
2.2.3 Oxidative degradation of alginates 
 Alginate was degraded to lower molecular weight alginate oligosaccharides via oxidative 
degradation following previously published protocols.40,41 Briefly, alginate (2.5 g) was dissolved 
in 15 wt% hydrogen peroxide (50 mL) and stirred at 85 °C for 1 h. The solution was filtered to 
remove any insoluble material. The resulting alginate oligosaccharides was precipitated from the 
filtered solution in ethanol, collected via centrifugation, washed copiously with ethanol, and dried 
in vacuo to yield a white powder. GPC measurements revealed the molecular weight of the starting 
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alginate material, as received, was 283 kDa with a dispersity (Ð) of 1.11. The average molecular 
weight of the alginate oligosaccharides (Alg5) was 4.68 kDa with a dispersity of 1.20. 
2.2.4  Synthesis of polyamine-modified alginates (AlgMW-alkyl amine) 
 Alginate starting materials were modified with either diethylenetriamine (DETA), bis(3-
aminopropyl)amine (DPTA), N-propyl-1,3-propanediamine (PAPA), or spermine (SPER) through 
covalent amide bond formation between the carboxylic acid moieties of alginate and the primary 
amines of the alkyl amine (Figure 2.1).27 Briefly, alginate (100 mg) was dissolved in 10 mL 
phosphate buffered saline (PBS; 10 mM, pH 6.5) together with a 2:1 molar ratio to 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and a 2:1 molar ratio of N-
hydroxysuccinimide (NHS) with respect to the carboxylic moeities of the alginate scaffold. The 
resulting solution was allowed to mix at room temperature for 30 min before adding a 4:1 molar 
ratio of the alkyl amine with respect to the carboxylic acid groups of the alginate scaffold to the 
reaction solution. After 24 h at room temperature, the amine-modified alginates were precipitated 
in methanol, collected via centrifugation, washed twice with methanol, and dried in vacuo to yield 
a white solid for each modification. 
Representative 1H NMR of alginate and the polyamine-modified alginates included the 
following peaks: 
Alg300 and Alg5: 1H NMR (600 MHz, D2O, δ) 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (OHCOCH), 4.90 (OCH(CHOH)O).  
Alg300-DETA and Alg5-DETA: 1H NMR (600 MHz, D2O, δ) 2.30-3.30 
(CH2CH2NHCH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 

















Alg300-DPTA and Alg5-DPTA: 1H NMR (600 MHz, D2O, δ) 1.60-1.80 
(CH2CH2CH2NHCH2CH2CH2NH2), 2.60-2.30 (CH2CH2CH2NHCH2CH2CH2NH2), 2.80-3.10 
(CH2CH2CH2NHCH2CH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O).  
Alg300-PAPA and Alg5-PAPA: 1H NMR (600 MHz, D2O, δ) 0.70-0.80 (NHCH2CH2CH3), 1.52 
(NHCH2CH2CH3), 1.85 (CH2CH2CH2NHCH2CH2CH3), 2.80-3.10 
(CH2CH2CH2NHCH2CH2CH3), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 
4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O).   
Alg300-SPER and Alg5-SPER: 1H NMR (600 MHz, D2O, δ) 1.13 (NHCH2(CH2)2CH2NH), 1.56 
(NHCH2CH2CH2NH), 1.80 (C(O)NHCH2CH2CH2NH), 2.20-2.40 (CH2CH2CH2NH, 
NHCH2(CH2)2CH2NH, NHCH2CH2CH2NH2), 2.68 (NHCH2CH2CH2NH2), 2.80-3.10 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O). 
 Representative 13C NMR of alginate and the polyamine-modified alginate included the 
following peaks: 
Alg300 and Alg5: 13C NMR (600 MHz, D2O, δ) 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 175.0 (CHC(O)).  
Alg300-DETA and Alg5-DETA: 13C NMR (600 MHz, D2O, δ) 39.0-47.0 
(C(O)NHCH2CH2NHCH2CH2NH2), 65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 
(OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 (CHC(O)).  
Alg300-DPTA and Alg5-DPTA: 13C NMR (600 MHz, D2O, δ) 26.9-29.5 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 37.6-46.0 (C(O)NHCH2CH2CH2NH, 
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NHCH2CH2CH2NH2), 65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 
160.0 (CHC(O)NH), 175.0 (CHC(O)).  
Alg300-PAPA and Alg5-PAPA: 13C NMR (600 MHz, D2O, δ) 10.9 (NHCH2CH2CH3), 20.0 
(NHCH2CH2CH3), 31.3-49.0 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH3), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)).  
Alg300-SPER and Alg5-SPER: 13C NMR (600 MHz, D2O, δ) 23.2 (NHCH2(CH2)2CH2NH), 34.8-
45.0 (C(O)NHCH2CH2CH2NH), 65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 
(OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 (CHC(O)).  
2.2.5 Synthesis of NO-releasing alginates 
 To form N-diazeniumdiolate NO donors on the alginate scaffolds, polyamine-modified 
alginate (45 mg) was dissolved in 50 mM NaOH (3 mL) in a 1-dram glass vial (Figure 2.2). The 
open vials were placed in a stainless steel reactor and stirred continuously using a magnetic stir 
bar. Oxygen was removed from the vessel by purging with argon (10 s, 7 bar) three times, followed 
by three additional long purges with argon (10 mins, 7 bar). The vessel was then pressurized to 10 
bar with NO gas and allowed to react for 3 d. The same argon purging protocol was then repeated 
to remove unreacted NO.  The NO-releasing alginates were then precipitated in methanol, 
collected by centrifugation, dried overnight in vacuo, and stored in vacuum sealed bags at -20 °C 





















2.2.6 Characterization of NO storage and release 
 Nitric oxide release was evaluated in real-time using a Sievers 280i Chemiluminescence 
NO analyzer (NOA; Boulder, CO). Each sample was analyzed before use to ensure stability of the 
stored material. Prior to analysis, the NOA was calibrated with air passed through a NO zero filter 
(0 ppm NO) and 25.87 ppm of NO standard gas (balance N2). In a typical measurement, NO-
releasing alginates (1 mg) were dissolved in 30 mL of PBS (10 mM, pH 7.4, 37 °C). The solution 
was purged with nitrogen gas at a flow rate of 70 mL/min to carry liberated NO from the solution 
to the analyzer. Additional nitrogen flow was supplied to the flask to match the collection rate of  
the instrument (200 mL/min). Nitric oxide analysis was terminated when NO levels fell below 10 
ppb of NO/mg of alginate (the limit of detection of the instrument). 
2.2.7 Planktonic bactericidal assay 
 P. aeruginosa and S. aureus bacterial cultures were grown from a frozen (-80 °C) stock 
overnight in TSB at 37 °C. A 500 µL aliquot of culture was grown in 50 mL of fresh TSB to a 
concentration of 108 colony forming units per mL (CFU/mL). A working bacterial stock was 
generated by plating the bacterial suspension on TSA and incubating at 37 °C overnight. The TSA 
bacterial stocks were prepared weekly and stored at 4 °C. For bactericidal assays, colonies of P. 
aeruginosa and S. aureus were taken from the TSA plate, inoculated in 3 mL TSB overnight at 37 
°C, and recultured in fresh TSB (50 mL) to a concentration of 108 CFU/mL. These cultures were 
centrifuged, resuspended in PBS, and diluted to 106 CFU/mL. Weighed samples of NO-releasing 
alginates and controls (non-NO-releasing alginates) were added to a 1-dram vial. Corresponding 
volumes of the 106 CFU/mL bacteria were then added to obtain a range of alginate concentrations 
(0.5 to 16 mg/mL). These solutions were incubated for 4 h at 37 °C. Blanks or untreated bacterial 
solutions were included in each experiment to ensure bacteria viability over the duration of the 
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experiment. Following treatment, the bacterial solutions were diluted serially (10- and 100-fold 
dilutions), spiral plated on TSA using an Eddy Jet spiral plater (IUL; Farmingdale, NY), and 
incubated overnight at 37 °C. Bacterial viability was determined using a Flash & Go colony 
counter (IUL; Farmingdale, NY). The minimum bactericidal concentration after a 4-hour exposure 
period (MBC4h) was defined as the minimum concentration required to achieve a 3-log reduction 
in bacterial viability relative to untreated cells (i.e., reduced bacterial counts from 106 to 103 
CFU/mL). The limit of detection for this counting method is 2.5 × 103 CFU/mL.42 The 
corresponding NO dose was calculated by multiplying the MBC4h of the alginate samples (mg/mL) 
with the measured NO released in PBS (pH 7.4; µmol NO/mg alginate) over the 4 h experimental 
window. 
2.2.8 Biofilm eradication assay 
 Similar to planktonic experiments, P. aeruginosa and S. aureus bacterial cultures were 
grown overnight in TSB at 37 ⁰C and recultured in fresh TSB to a concentration of 108 CFU/mL. 
These solutions were diluted to 106 CFU/mL in sterile media (P. aeruginosa, TSB; S. aureus, TSB 
+ 0.1 % glucose) and grown for 48 h at 37 ⁰C with gentle shaking. The formed biofilms were 
separated from the growth media by pipetting the biofilm mass. Biofilms (250 µL) were combined 
with 750 µL of PBS and added to 1-dram vials containing premeasured samples of NO-releasing 
and control alginates, with final alginate concentrations ranging from 4 to 64 mg/mL. The samples 
were incubated with gentle shaking for 24 h at 37 ⁰C. Blanks were included in each experiment to 
ensure bacterial viability over the duration of the experiment. The dispersed biofilms were 
vortexed, serially diluted (10-, 100-, 1000-, and 10,000-fold dilutions), plated on TSA plates using 
an Eddy Jet spiral plater, and incubated overnight at 37 °C. Bacterial viability was assessed using 
a Flash & Go colony counter.  The minimum biofilm eradication concentration at 24 h (MBEC24h) 
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was defined as the minimum concentration required to achieve a 5-log reduction in bacterial 
viability compared to untreated cells (i.e., reduced bacterial counts from 108 to 103 CFU/mL). The 
corresponding NO dose was calculated by multiplying the MBEC24h of the alginate samples 
(mg/mL) with the NO released in PBS (pH 7.4; µmol NO/mg alginate) over the testing period. 
2.2.9 Time-Based Biofilm Eradication Assay 
 P. aeruginosa biofilms were grown and treated with NO-releasing alginates (8 mg/mL) 
following the same protocol as for the biofilm eradication assays. Blanks were included to ensure 
bacteria viability over the duration of the experiment. The samples were incubated with gentle 
shaking at 37 °C for 1-24 h before plating on TSA plates using an Eddy Jet spiral plater and 
incubating overnight at 37 °C. Bacterial viability was assessed using a Flash & Go colony counter. 
A similar experiment was carried out at the MBEC24h for Alg-PAPA/NO and Alg-SPER/NO for 
comparison to time-based killing at 8 mg/mL. 
2.2.10 In vitro cytotoxicity assay 
 A549 human respiratory epithelial cells were grown in RPMI 1640 media supplemented 
with 10 vol% FBS and 1 wt% penicillin streptomycin. Cells were incubated in 5 vol % CO2 under 
humidified/aerobic conditions at 37 °C. After reaching 80% confluency, the cells were seeded onto 
96-well polystyrene plates at a density of 2 × 103 cells/well, and incubated for 24 h at 37 °C. The 
supernatant was then aspirated and replaced with 100 µL of alginate in fresh growth medium with 
a final concentration of test material equivalent to MBEC24h against P. aeruginosa or S. aureus 
biofilms. After 24 h incubation at 37 °C, the supernatant was aspirated and the wells containing 
the cells were washed with PBS. A 100 µL mixture of RPMI 1640/MTS/PMS (105/20/1, v/v/v) 
was added to each well. After an additional 90 min incubation period (37 °C), the absorbances of 
the wells were measured at 490 nm using a Thermoscientific Multiskan EX plate reader (Waltham, 
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MA). A blank mixture of RPMI 1640/MTS/PMS and untreated cells were used as the blank and 
control, respectively. Cell viability for each sample was calculated as follows:  
%  𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
(𝐴𝑏𝑠490 − 𝐴𝑏𝑠𝑏𝑙𝑎𝑛𝑘)
(𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝐴𝑏𝑠𝑏𝑙𝑎𝑛𝑘) 
x 100                                      (eq.1). 
 
 
2.3 Results and Discussion  
 Alginates are found in nature as polydisperse, water soluble high molecular weight 
polymers (200-500 kDa).26,27 Prior research has demonstrated the ease by which these polymers 
undergo oxidative degradation to form lower molecular weight oligosaccharides.41,43 To that end, 
reaction conditions were optimized to yield alginate oligosaccharides with molecular weights of 
~5 kDa to compare to previously reported water-soluble NO-releasing biopolymer systems.40 The 
addition of secondary amine-bearing functional groups to the alginate backbone allows for the 
subsequent formation of N-diazeniumdiolate NO donors. This class of NO donor facilitates 
spontaneous NO release in physiological media. In the present study, a series of small molecule 
NO donor precursors were linked to the carboxylic acid functional groups of both high molecular 
weight (~300 kDa) and low molecular weight (~5 kDa) alginates via EDC/NHS reactions (Figure 
2.1) to enable tuning of the NO-release kinetics. Of note, pH 6.5 phosphate buffer saline was 
employed to avoid gelation of alginate.30 The reaction was optimized to maximize alkyl amine 
modification while minimizing the possibility of crosslinking between the alginate backbone and 
the diamine functional groups (i.e., DETA, DPTA, SPER). The average molecular weight (Mw) 
proved to be dependent on the molar excess of the alkyl amine functional group added to the 
reaction solution (Table 2.1). For example, keeping the molar ratio at 1:1 resulted in a drastic 
increase in the molecular weight of the alkyl amine-modified alginate (e.g. Alg300-SPER with 
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Mw ~700 kDa) suggesting possible crosslinking with the biopolymer. Increasing the molar ratio 
of the diamine functional group minimized this effect (Table 2.1). This trend was observed with 
the high molecular weight alginate systems and not with the low molecular weight materials. No 
gel phase was formed at the optimized parameters for the reaction.  Polyamine functionalization 
was also confirmed using 1H NMR, 13C NMR, and elemental analysis (Figures 2.3, 2.4, and 2.5). 
The nitrogen content of the alginates increased from 0 to 5-8 wt% with amine modification (Table 
2.2). This value translates to ~40-50 % modification of the carboxylic acid functional groups.  A 
positive shift in zeta potential was also noted upon amine modification, corresponding to the 
formation of protonated amine groups at pH 7.4 (Table 2.2). 
2.3.1 Synthesis of N-diazeniumdiolate-modified biopolymers 
 The secondary amine-modified alginates were charged with high pressures of NO (10 bar) 
in basic aqueous solution (50 mM NaOH) to allow efficient formation of N-diazeniumdiolate NO 
donors (Figure 2.2). The formation of the NO donors was confirmed using UV-vis spectroscopy 
and the appearance of a characteristic absorbance band at 253 nm (Figure 2.6).  
 Representative NO-release profiles of the N-diazeniumdiolate-functionalized alginates in 
PBS (pH 7.4) at 37 °C are shown in Figure 2.7. Both high and low molecular weight alginates 
were found to have similar NO totals that were comparable to other macromolecular NO-releasing 
biopolymeric scaffolds (0.3-0.6 µmol/mg).40,44–47 A broad range of NO-release kinetics was also 
observed for the alginate scaffolds with Alg300-PAPA/NO and Alg5-PAPA/NO having the 
shortest NO-release half-lives (~0.5 and ~0.3 h, respectively) or fastest NO donor breakdown. In 
contrast, the NO release of Alg300-DETA/NO and Alg5-DETA/NO was highly prolonged (NO-
release half-lives of ~40 and 29 h, respectively). The NO-release duration varied as a function of 










Table 2.1 Molecular weight of alkyl amine-modified alginate as a function of added alkyl 
amine ratio.a 
Biopolymer 
Molar excess of alkyl amine to -
COOH moieties of alginate 
Mw (kDa) PDI 
Alg300-DETA 
1 581 1.26 
2 409 1.32 
4  388 1.35 
Alg300-DPTA 
1 548 1.11 
2 439 1.21 
4  397 1.23 
Alg300-PAPA 
1 335 1.42 
2 324 1.35 
4  323 1.31 
Alg300-SPER 
1 711 1.63 
2 512 1.60 
4  459 1.45 
Alg5-DETA 
1 5 1.50 
2 5 1.82 
4 5 2.06 
Alg5-DPTA 
1 6 1.51 
2 6 1.22 
4 6 1.44 
Alg5-PAPA 
1 5 1.65 
2 6 1.53 
4 7 1.49 
Alg5-SPER 
1 7 1.47 
2 7 1.73 
4 8 1.82 
aAverage molecular weight (Mw) and polydispersity index (PDI) was measured using GPC-multi-












Figure 2.3 (A) Representative 1H NMR spectrum for Alg300, and (B) representative 13C NMR 
spectrum for Alg300 in D2O. Control 












Figure 2.4 Representative 1H NMR spectra for (A) DETA-, (B) DPTA-, (C) PAPA-; and, (D) 










Figure 2.5 Representative 13C NMR spectra for (A) DETA-, (B) DPTA-, (C) PAPA-; and, (D) 












Table 2.2 Elemental (CHN) analysis, zeta potential measurements, and reaction yields for 













Alg300 30.4 ± 0.4 4.7 ± 0.4 0.0 ± 0.0 -47.2 ± 2.8 - 
Alg300-DETA 35.1 ± 0.5 7.4 ± 0.5 7.6 ± 0.5 -24.2 ± 2.4 92 
Alg300-DPTA 34.7 ± 0.6 7.4 ± 0.6 7.5 ± 1.1 -23.1 ± 2.9 89 
Alg300-PAPA 34.7 ± 1.1 5.4 ± 0.0 6.7 ± 0.2 -33.4 ± 1.6 86 
Alg300-SPER 40.4 ± 2.0 7.6 ± 0.5 8.3 ± 0.1 -13.0 ± 2.5 77 
Alg5 29.3 ± 1.3 5.1 ± 0.3 0.0 ± 0.0 -48.0 ± 4.1 - 
Alg5-DETA 34.2 ± 0.5 7.6 ± 0.6 7.8 ± 0.8 -23.5 ± 2.7 89 
Alg5-DPTA 33.6 ± 0.4 6.4 ± 0.1 6.4 ± 0.2 -20.0 ± 3.5 80 
Alg5-PAPA 30.7 ± 0.1 5.3 ± 1.0 4.7 ± 0.7 -28.5 ± 3.3 84 
Alg5-SPER 38.2 ± 0.4 7.4 ± 0.2 8.2 ± 1.1 -18.3 ± 3.9 82 








Figure 2.6 Representative UV-vis spectra for (A) DETA-, (B) DPTA-, (C) SPER-; and, (D) 










Figure 2.7 (A) Real time NO-release profiles for the first 1 h and (B) plot of total NO release 
vs. time for NO-releasing DETA- (solid), DPTA- (dash), SPER- (dash-dot); and PAPA- (dot) 
modified alginates measured via chemiluminescence in pH 7.4 PBS. 
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molecule NO donors (i.e., DETA, DPTA, PAPA, and SPER).48,49 Following previous reports, a 
decrease in half-life was observed for the NO-releasing alginates as chain length of the alkyl amine 
functional group increased.38,48,49 The positively charged primary amine terminal moiety stabilizes 
the negative charge of the N-diazeniumdiolate NO donor, resulting in an increase in half-life of 
the anion for DETA-, DPTA-, and SPER-modified alginates compared to that of the PAPA-
modified scaffold (Figure 2.2).49 The molecular weight of the alginate also dramatically influenced 
the NO release. For example, the Alg5 oligosaccharides released NO more rapidly than the larger 
Alg300 analogs modified with the same amine precursor (Table 2.3). In addition, negligible NO 
release was observed for control alginates modified with ethylenediamine, an alkyl amine lacking 
secondary amine moieties, suggesting that the primary amines do not react with NO under the 
reported conditions used for N-diazeniumdiolate formation (~0.03 µmol/mg total NO). Overall, 
these experiments demonstrate exquisite NO-release tunability by simply varying the molecular 
weight of the scaffold and/or the chemical structure of an amine precursor grafted onto the alginate 
backbone. 
2.3.2 Antibacterial action against planktonic bacteria 
 The antibacterial activity of control and NO-releasing alginates was evaluated against P. 
aeruginosa and S. aureus, two prevalent pathogens associated with infections.6,50 Bacterial 
viability assays were performed under static conditions to extract the minimum bactericidal 
concentration of the test agent required to elicit a 3-log reduction (i.e., 99.9% killing) in bacterial 
viability over 4 h (MBC4h). The non-NO-releasing controls did not significantly impact bacterial 
viability up to 16 mg/mL for both P. aeruginosa and S. aureus (Figure 2.8).  In contrast, low 
concentrations (< 8mg/mL), led to a 3-log reduction (≥99.9 %) in bacterial viability for each of the 














Table 2.3 Nitric oxide-release properties of N-diazeniumdiolate-functionalized alginates in 






t1/2d (h) tde (h) 
t[NO]4hf 
(µmol/mg) 
Alg300-DETA/NO 0.40 ± 0.04 232 ± 78 13.1 ± 5.8 40.3 ± 14.2 0.10 ± 0.01 
Alg300-DPTA/NO 0.42 ± 0.04 428 ± 124 3.4 ± 0.6 16.1 ± 2.9 0.23 ± 0.01 
Alg300-PAPA/NO 0.61 ± 0.13 2110 ± 1240 0.5 ± 0.1 6.1 ± 1.0 0.59 ± 0.11 
Alg300-SPER/NO 0.65 ± 0.16 1236 ± 240 1.3 ± 0.4 14.6 ± 3.5 0.49 ± 0.11 
Alg5-DETA/NO 0.33 ± 0.03 101 ± 30 9.8 ± 0.1 29.3 ± 1.7 0.08 ± 0.03 
Alg5-DPTA/NO 0.48 ± 0.02 1157 ± 227 1.2 ± 0.1 8.7 ± 0.5 0.45 ± 0.10 
Alg5-PAPA/NO 0.55 ± 0.11 3543 ± 908 0.3 ± 0.0 3.9 ± 0.3 0.55 ± 0.11 
Alg5-SPER/NO 0.38 ± 0.03 477 ± 307 1.6 ± 0.2 11.1 ± 0.8 0.25 ± 0.04 
aError represent standard deviation for n ≥ 3 experiments. bTotal NO released. cMaximum flux 






Figure 2.8 Antibacterial efficacy of high (square) and low (circle) molecular weight NO-
releasing (filled) and control (hollow) (A) DETA-, (B) DPTA-, (C) SPER-; and, (D) PAPA-
modified alginates against planktonic P. aeruginosa and S. aureus.  Error bars represent 
















Table 2.4 Minimum bactericidal concentrations (MBC4h) of NO-releasing alginates against 
planktonic P. aeruginosa and S. aureus.a 
Biopolymer 









Alg300-DETA/NO 4 0.40 ± 0.04 8 0.80 ± 0.08 
Alg300-DPTA/NO 2 0.45 ± 0.01 4 0.88 ± 0.02 
Alg300-PAPA/NO 2 1.18 ± 0.24 8 4.75 ± 0.95 
Alg300-SPER/NO 1 0.49 ± 0.11 4 1.96 ± 0.45 
Alg5-DETA/NO 2 0.20 ± 0.02 4 0.40 ± 0.04 
Alg5-DPTA/NO 0.25 0.11 ± 0.01 2 0.92 ± 0.01 
Alg5-PAPA/NO 0.5 0.30 ± 0.06 8 4.69 ± 0.88 
Alg5-SPER/NO 0.25 0.07 ± 0.01 2 0.54 ± 0.09 
aError represent standard deviation for n ≥ 3 experiments. bNO dose was calculated from NO 




alginate requiring the least amount to achieve bactericidal activity (Table 2.2). Other studies have 
reported that positively charged scaffolds associate more readily with bacteria with a concomitant 
enhancement in bactericidal action.40,51 The alginates herein followed a similar trend, with Alg300-
SPER/NO (zeta potential -13.0 mV) eradicating bacteria at the lowest concentration while Alg300-
PAPA/NO (-33.4 mV) necessitated the largest (Table 2.2). Nitric oxide-release kinetics also 
influenced the bactericidal action for the alginate materials, with the fastest (Alg300-PAPA/NO) 
and slowest (Alg300-DETA/NO) NO-releasing systems requiring greater concentrations relative 
to alginates with moderate release kinetics. Despite larger overall NO payloads (~0.6 µmol/mg), 
the faster NO release associated with Alg300-PAPA/NO may liberate NO prematurely prior to the  
alginate associating with the bacteria, which could then facilitate more efficient delivery of lethal 
NO doses to the bacteria. Indeed, other macromolecular NO-release systems (e.g., silica) required 
20 min to elicit NO build up within P. aeruginosa as studied via confocal microscopy.15 The 
elevated concentrations of NO-releasing alginates needed for eradication using Alg300-DETA/NO 
are likewise attributed to insufficient NO released over the 4h MBC assay (~0.10 µmol/mg) 
compared to the other NO donor modifications (i.e., DPTA, PAPA, SPER).  
 A similar dependence on NO-release kinetics was observed for the low molecular weight 
alginates with both Alg5-SPER/NO and Alg5-DPTA/NO having the lowest MBC4h. Of note, the 
concentrations of NO-releasing alginate oligosaccharides required to eradicate bacteria were 
significantly lower than their high molecular weight counterparts. Similar size-dependent effects 
have been previously reported for NO-releasing silica, albeit silica is a dense (i.e., hard) 
material.20,52 Liu et al. demonstrated similar beneficial antibacterial action as a function of 
biopolymer molecular weight.53 Our results suggest that the use of lower molecular weight 
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alginates allows for more efficient NO delivery, in turn reducing the required NO dose for 
eradicating planktonic bacteria.  
 For both high and low molecular weight alginates, greater concentrations of NO-releasing 
derivations were necessary to achieve bactericidal activity against S. aureus relative to P. 
aeruginosa (Table 2.4).  The thicker peptidoglycan layer of S. aureus likely decreases the diffusion 
of NO into the bacterium, necessitating larger doses of the macromolecule to achieve equivalent 
killing.54 Gram-negative bacteria such as P. aeruginosa generally have a more lipid-rich outer 
membrane and thinner peptidoglycan sheets, increasing their susceptibility to NO and other 
permeating antimicrobials.54 
2.3.3 Antibiofilm efficacy 
 In addition to exhibiting bactericidal action against planktonic bacteria, the NO-releasing 
alginate scaffolds were also highly effective against P. aeruginosa and S. aureus biofilms. Similar 
to the planktonic assays, the concentrations of NO-releasing alginate oligosaccharides were lower 
for eradicating the biofilms relative to the higher molecular weight systems (Figure 2.9, Table 2.5), 
further emphasizing the role of NO delivery scaffold on bactericidal action. Greater biocidal action 
was also noted against P. aeruginosa over S. aureus biofilms. Worley et al. previously reported 
reduced penetration of NO-releasing poly(amido amine) dendrimers into S. aureus biofilms 
relative to P. aeruginosa.22 Such differences can be attributed to the biofilm architectures. The 
exopolysaccharide matrix of S. aureus biofilms produce greater levels of polysaccharide and 
extracellular proteins that hinder the diffusion of antibacterial agents such as NO.22,55 Coupled with 
the peptidoglycan differences, these structural advantages account for the lower susceptibility of 
S. aureus biofilms. Nevertheless, the broad-spectrum action of NO is clearly capable of eradicating 





Figure 2.9 Antibiofilm efficacy of high (square) and low (circle) molecular weight NO-
releasing (filled) and control (hollow) (A) DETA-, (B) DPTA-, (C) SPER-; and, (D) PAPA-
modified alginates against planktonic P. aeruginosa and S. aureus.  Error bars represent 











Table 2.5 Minimum biofilm eradication concentrations (MBEC24h) of NO-releasing 
alginates against P. aeruginosa and S. aureus biofilms.a 
Biopolymer 









Alg300-DETA/NO 8 2.6 ± 0.5 16 6.2 ± 0.2 
Alg300-DPTA/NO 8 3.4 ± 0.0 16 6.8 ± 0.1 
Alg300-PAPA/NO 32 19.6 ± 3.8 64 39.2 ± 7.6 
Alg300-SPER/NO 16 10.3 ± 1.8 32 20.7 ± 3.6 
Alg5-DETA/NO 4 1.8 ± 0.5 8 3.6 ± 1.1 
Alg5-DPTA/NO 4 1.7 ± 0.2 4 1.7 ± 0.2 
Alg5-PAPA/NO 16 9.8 ± 2.0 16 9.8 ± 2.0 
Alg5-SPER/NO 4 1.3 ± 0.2 8 2.8 ± 0.2 
aError represent standard deviation for n ≥ 3 experiments. bNO dose was calculated from 24 h 




 Following the size-dependent trend observed in the planktonic studies, the less negatively 
charged alginate systems required lower alginate concentrations to elicit biocidal activity, with the 
exception of Alg300-SPER/NO. Despite having the least negative charge of the evaluated alginate 
systems (Table 2.2), the large NO flux and rapid release half-life for Alg300-SPER/NO (Table 
2.3) likely results in undesirable NO donor breakdown similar to that noted for both Alg300-
PAPA/NO and Alg5-PAPA/NO.  In this respect, the overall biocidal efficacy of the NO-releasing 
scaffold depends on both the charge of the scaffold and the NO-release kinetics. Alginate scaffolds 
with moderate to extended NO-release durations (t1/2 ≥ 2 h) consistently require lower alginate 
concentrations and NO doses to eradicate biofilm-based bacteria, regardless of alginate molecular 
weight or bacteria Gram class. In this regard, the slower, sustained NO release ensures more 
effective NO delivery. This result is in agreement with previous studies using different NO-
releasing systems.20,23,24 
 P. aeruginosa biofilms were treated with equal concentrations (8 mg/mL) of each high 
molecular weight NO-releasing alginate (Figure 2.10A) to study bacterial viability as a function 
of release kinetics. The high molecular weight alginate scaffolds were selected for this experiment 
as they demonstrated the largest range in NO-release kinetics. A concentration of 8 mg/mL 
represented the lowest MBEC24h for the Alg300 systems. At 1 h, treatment with either Alg300-
PAPA/NO or Alg300-SPER/NO resulted in a 1- to 2-log reduction in biofilm bacterial viability, 
as expected based on the NO-release half-lives for the two NO-releasing alginates (~0.5-1.4 h). 
However, the low NO levels released from the fast NO-releasing alginate at longer durations were 
insufficient for bacterial killing, with P. aeruginosa viability recovering to ~108 CFU/mL after 4 
h. In contrast to the fast NO-release systems, the slower NO-releasing alginate scaffolds (~4 and 






Figure 2.10 Time-based bactericidal efficacy of Alg300-DETA/NO (square), Alg300-
DPTA/NO (circle), Alg300-SPER/NO (triangle), and Alg300-PAPA/NO (diamond). 
Comparison of all high molecular weight NO-releasing alginates at equivalent concentrations 
of 8 mg/mL is presented in (A), and the time-based killing of the fast NO-releasing systems 
(Alg300-SPER/NO and Alg300-PAPA/NO) at their respective MBEC24h is presented in (B). 







in bacteria viability at this same concentration (i.e., 8 mg/mL), eventually leading to a 5-log 
reduction after 8 h of treatment. At the larger concentrations required to achieve the MBEC24h, 
both Alg300-PAPA/NO (32 mg/mL) and Alg300-SPER/NO (16 mg/mL) elicited a 5-log reduction 
in bacterial viability after only 1 and 4 h exposures, respectively, but resulted in observable 
bacterial growth after 24 h (Figure 2B). The greater alginate (and NO) concentrations improved 
the antibacterial efficacy of the faster NO-releasing alginates through rapid killing induced by the 
large initial NO burst. Overall, these results suggest that slower, more sustained NO release is 
preferred for biofilm eradication at the smaller alginate concentrations. 
2.3.4 In vitro cytotoxicity against A549 cells 
 An attractive property of alginates for biomedical applications is the perceived favorable 
toxicity to mammalian cells. Of course, the influence of the N-diazeniumdiolate modification on 
cytotoxicity might elicit unexpected toxicity. Thus, the cytotoxicity of the alginate scaffolds was 
evaluated using human respiratory epithelial (A549) cells at the alginate MBECs determined to 
kill P. aeruginoa and S. aureus.57–61 As shown in Figure 2.11, neither control nor the NO-releasing 
alginates exhibited significant toxicity (i.e., cell viabilities >70%) against A549 cells at the 
determined MBEC24h values, regardless of size (i.e., molecular weight) or charge, highlighting the 
advantage of these biopolymers as antibiofilm agents. The low to negligible toxicity of the NO-
releasing alginates at the bactericidal concentrations shows promise for the use of these 
macromolecules as antibacterial and antibiofilm treatment for wound healing and respiratory 








Figure 2.11 Viability of A549 human respiratory epithelial cells exposed to control and NO-
releasing (white) and control (dash) alginates at the MBEC24h against (A) P. aeruginosa and 







 N-diazeniumdiolate-modified alginate scaffolds were synthesized with diverse NO-release 
kinetics (0.5-13 h half-lives) and antibacterial properties. The biocidal efficacies of the NO-
releasing alginate materials were demonstrated against both planktonic and biofilm-based forms 
of P. aeruginosa and S. aureus. Alginate modifications that exhibited slow and sustained NO 
release (e.g., Alg300-DPTA/NO and Alg300-DETA/NO) proved to be highly effective against 
bacterial biofilms, requiring lower NO-releasing alginate to elicit eradication. The molecular 
weight of the scaffold proved important with the oligosaccharides eliciting the greatest bactericidal 
action. Both amine-modified (control) and NO-releasing alginates exerted minimal toxicity against 
A549 cells, demonstrating the biocompatible properties of the bare scaffold. Nitric oxide-releasing 
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CHAPTER 3: RHEOLOGY OF MUCUS TREATED WITH NITRIC OXIDE-RELEASING 
ALGINATES 
3.1 Introduction 
 Airway mucus represents the first line of defense in the respiratory tract against invading 
pathogens (e.g., bacteria), dust, spores, pollen, and other chemical irritants.1–3 Mucus is comprised 
of approximately 95% water, with the balance consisting of proteins, lipids, salts, and mucin 
glycoproteins (i.e., the main component that determines its gel-like properties).4,5  The consistency 
of mucus is often described in terms of rheological properties, particularly viscosity (resistance to 
flow) and elasticity (resistance to deformation) due to this complexity.5 Excessive, long-term 
mucus production (i.e., mucus hypersecretion) is a major pathological feature of severe respiratory 
diseases, such as cystic fibrosis (CF).1–3,6 Accumulation of highly viscous and elastic mucus 
obstructs the airways and provides a suitable environment for the colonization of bacteria.7 The 
presence of persistent chronic infections and impeded mucus clearance leads to a decline in lung 
function and ultimately patient mortality. 
Currently used treatment strategies focused on combining therapies that target bacterial 
infections (i.e., antibiotics) with those that alter mucus rheology (i.e., mucolytics). Nitric oxide 
(NO), an endogenously-produced free radical, holds promise as a potential therapeutic agent for 
treating respiratory diseases due to its broad spectrum antibacterial activity against planktonic and 
biofilm-based bacteria.8–15 Present studies indicated that bacteria are unlikely to foster resistance 
to NO owing to the multi-mechanistic pathways (e.g., nitrosation of thiols on bacterial proteins) 
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involved in NO’s antibacterial action.16,17 While initial studies have demonstrated the efficacy of 
exogenous NO in the gas form, the hazards associated with the use of pressurized cylinders and 
NO’s high reactivity in biological media has to date limited its therapeutic utility.18 Research has 
thus also focused on the development of water soluble macromolecules capable of storing and 
releasing NO under specific environmental conditions as an alternative to direct NO inhalation.18,19 
The use of the N-diazeniumdiolate NO donor-modified macromolecular scaffolds is particularly 
attractive due to the NO donor’s ability to spontaneously release NO under physiological 
conditions (e.g., 37 °C, pH 6.5 in CF mucus),9,20,21 a property critical for sustained NO delivery in 
the lungs via intermittent (e.g, twice daily) treatment.18 Although the activity of NO-releasing 
macromolecules as antibacterial agents for the treatment of respiratory infections has been well 
documented,8,9 its potential impact on mucus rheology remains uncertain. Initial studies with NO-
releasing chitosan have demonstrated NO’s ability to damage the three-dimensional mucin 
network and reduce mucin size.20 While this report indicated NO’s potential as a mucolytic, a 
systematic evaluation of the impact of NO-release properties (e.g., release kinetics) and the effect 
of the macromolecule properties (e.g., molecular weight) of the material for pulmonary NO 
delivery is still required for further development of NO as a dual-action (i.e., antibacterial and 
mucolytic) therapy. Previous reports have characterized the antibacterial properties of NO-
releasing materials as a function of macromolecular water solubility, charge, and NO-release 
kinetics.22–25 We believe that the same properties are likely to influence the mucolytic activity of 
NO-releasing systems.   
Alginate, an anionic biopolymer composed of 1,4-linked α-l-guluronic acid (G) and β-d-
mannuronic acid (M) units, holds particular promise as a NO donor scaffold for the development 
of inhaled NO therapeutics (via nebulization) due to its high water solubility, low toxicity, and 
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favorable biocompatibility.26–30 Previous studies with low molecular weight alginate 
oligosaccharides demonstrated alginate’s ability to modulate mucin assembly, and reduce the 
elastic and viscous properties of CF sputum.6,31–33 The biopolymer’s ability to alter mucus structure 
occurs by inhibiting interpolymer crosslinks and interfering with intramolecular interactions 
between the mucin glycoproteins. We hypothesize that combining alginate with NO’s antibacterial 
and mucolytic action (by interfering with the disulfide bonds the stitch mucin monomers into long-
chain polymers) may result in a favorable dual-action therapeutic for treating obstructive 
respiratory diseases plagued with chronic infection.20,34  
Bulk rheological properties of mucus are tightly correlated to its clearance from the lung.5  
Therefore, reducing the viscoelastic burden of pathological mucus is important in the treatment of 
muco-obstructive pulmonary diseases such as CF and COPD. Herein, we evaluated the ability of 
NO-releasing alginates to alter the bulk viscoelastic properties of human bronchial epithelial 
(HBE) mucus using parallel plate rheology. Alginate modified with different alkyl amine groups 
provided a platform to tune NO payloads and release kinetics depending on the precursor amine 
structure. The effect of NO-release kinetics, alginate concentration, and select biopolymer 
properties (e.g., molecular weight and charge) on mucus rheology were also examined with similar 
goals.  
 
3.2 Experimental Section 
3.2.1 Materials 
Alginic acid sodium salt from brown algae (low viscosity), bis(3-aminopropyl) amine 
(DPTA), diethylenetriamine (DETA), N-propyl-1,3-propanediamine (PAPA), spermine (SPER), 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimde 
94 
 
(NHS), p-anisaldehyde, p-toluenesulfonyl chloride, ethanolamine and N-acetyl cysteine (NAC) 
were purchased from Sigma-Aldrich (St. Louis, MO). Medium molecular weight chitosan (95% 
degree of deacetylation) was purchased from Primex (Siglufjordur, Iceland). Common laboratory 
salts and solvents were purchased from Fisher Scientific (Fair Lawn, NJ). Unless otherwise 
specified, all chemicals were used as received without further purification. Argon (Ar), carbon 
dioxide (CO2), nitrogen (N2), nitric oxide (NO) calibration (25.87 ppm, balance N2), and pure NO 
(99.5%) gas cylinders were purchased from Airgas National Welders (Raleigh, NC). Distilled 
water was purified to a resistivity of 18.2 MΩ•cm and a total organic content of ≤6 ppb using a 
Millipore Milli-Q UV Gradient A10 System (Bedford, MA). 
3.2.2 Instrumentation 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker (600 
MHz) spectrometer. Elemental (carbon, hydrogen, and nitrogen; CHN) analysis was performed 
using a PerkinElmer Elemental Analyzer Series 2400 Instrument (Waltham, MA). Zeta potential 
measurements were collected in phosphate buffer (PB; 10 mM; pH 6.5) using a Zetasizer Nano 
(Malvern Instruments, UK). Rheological measurements were carried out using a TA Discovery 
Hybrid Rheometer 3 (DHR3; New Castle, DE) with a 20 mm diameter parallel plate set to a gap 
thickness of 50 mm. Gel permeation chromatography (GPC) measurements were collected out in 
0.1 M sodium nitrate using an aqueous GPC-multi-angle light scattering system equipped with a 
Waters 2414 refractive index detector (Milford, MA) coupled to a Wyatt miniDawn TREOS multi-





3.2.3 Oxidative degradation of biopolymers 
High molecular weight alginate and medium molecular weight chitosan biopolymers were 
degraded to lower molecular weights following previously published protocols.10,25,35 Briefly, the 
biopolymer (2.5 g) was dissolved in hydrogen peroxide (50 mL) and stirred in an oil bath for 1-4 
h. The concentration of the hydrogen peroxide in the solution (15-30 wt% in water), temperature 
(70-85 °C), and duration of the reaction were varied to obtain alginate oligosaccharides with a 
range of molecular weights (Table S1). The resulting solution was filtered to remove insoluble 
material. The alginate oligosaccharides were collected in and washed copiously with ethanol 
before drying in vacuo to yield a white powder. Alternatively, chitosan was stirred in 15 wt% 
hydrogen peroxide at 85 °C for 1 h with the resulting oligosaccharides collected in acetone and 
washed copiously with acetone. The chitosan oligosaccharides (COS) had an average molecular 
weight of 4.38 kDa and dispersity of 1.2 as determined by GPC measurements (Table 3.2). 
3.2.4  Synthesis of polyamine-modified alginates (AlgMW-alkyl amine) 
The alginate oligosaccharides were modified with either DETA, DPTA, PAPA, or SPER 
following a previously published protocol.25 Briefly, low molecular weight alginate (100 mg) was 
dissolved in 10 mL phosphate buffered saline (PBS; 10 mM, pH 6.5) with a 2:1 molar ratio of 
EDC and a 2:1 molar ratio of NHS with respect to the carboxylic acid moeities on the alginate 
biopolymer. The reaction was left to stir for 1 h. A 4:1 molar ratio of the alkyl amine with respect 
to the carboxylic acid groups of the alginate biopolymer was then added dropwise to the mixture. 
The reaction was allowed to proceed for 24 h at room temperature under constant stirring. The 
amine-modified alginates were precipitated in methanol and collected by centrifugation, washed 


























Alg10 1 h 15 70 10,980 2.05 
Alg5 1 h 15 85 4,680 1.22 
Alg1 4 h 30 85 1,447 2.10 
aAverage molecular weight (Mw) and polydispersity index (PDI) were measured using 




















Mwd (Da) PDId 
Alg300 0.0 ± 0.0 -40.4 ± 3.2 282,000 1.11 
Alg10 0.1 ± 0.0 -30.2 ± 5.0 9,184 1.14 
Alg5 0.0 ± 0.0 -31.3 ± 0.8 4,680 1.22 
Alg5-DETA 7.8 ± 0.8 -17.5 ± 3.4 5,200 2.06 
Alg5-DPTA 6.4 ± 0.2 -14.1 ± 1.5 6,000 1.44 
Alg5-SPER 8.2 ± 1.1 -12.4 ± 0.7  7,900 1.82 
Alg5-PAPA 5.7 ± 0.7 -22.8 ± 2.2 6,700 1.49 
Alg5-PAPA-DPTA 11.2 ± 0.7 -15.3 ± 3.1 7,200 1.87 
Alg1 0.1 ± 0.1 -22.6 ± 4.5 1,447 1.42 
COS 5.2 ± 0.3 1.9 ± 0.3 4,380 1.20 
COS-EA 6.3 ± 0.2 5.6 ± 1.3 5,610 1.70 
aError represents standard deviation for n ≥ 3 experiments. bMeasured by elemental 
analysis. cMeasured in phosphate buffer (pH 6.5). dMeasured using a gel permeation 





A hybrid alginate system modified with both PAPA and DPTA was also synthesized 
following similar steps. A 4:1 molar ratio of PAPA with respect to the carboxylic acid groups of 
alginate were first added dropwise to the solution prior to addition of a 4:1 molar ratio of DPTA 
with respect to the same groups. The reaction was allowed to proceed for 24 h at room temperature 
before being collected and copiously washed with methanol to yield a white powder.  
Representative 1H and 13C NMR of alginate and the polyamine modified alginates included 
the following peaks: 
Alg300, Alg 10, Alg5 and Alg1: 1H NMR (600 MHz, D2O, δ) 3.60-4.05 (OCHCH(OH)CH(OH)), 
4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (OHCOCH), 4.90 (OCH(CHOH)O). 13C NMR (600 MHz, 
D2O, δ) 65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 175.0 
(CHC(O)). 
Alg5-DPTA: 1H NMR (600 MHz, D2O, δ) 1.60-1.80 (CH2CH2CH2NHCH2CH2CH2NH2), 2.60-
2.30 (CH2CH2CH2NHCH2CH2CH2NH2), 2.80-3.10 (CH2CH2CH2NHCH2CH2CH2NH2), 3.60-
4.05 (OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 
(OCH(CHOH)O). 13C NMR (600 MHz, D2O, δ) 26.9-29.5 (C(O)NHCH2CH2CH2NH, 
NHCH2CH2CH2NH2), 37.6-46.0 CH2 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)).  
Alg5-DETA: 1H NMR (600 MHz, D2O, δ) 2.30-3.30 (CH2CH2NHCH2CH2NH2), 3.60-4.05 
(OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 
(OCH(CHOH)O). 13C NMR (600 MHz, D2O, δ) 39.0-47.0 (C(O)NHCH2CH2NHCH2CH2NH2), 
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65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 
175.0 (CHC(O)).  
Alg5-PAPA: 1H NMR (600 MHz, D2O, δ) 0.70-0.80 (NHCH2CH2CH3), 1.52 (NHCH2CH2CH3), 
1.85 (CH2CH2CH2NHCH2CH2CH3), 2.80-3.10 (CH2CH2CH2NHCH2CH2CH3), 3.60-4.05 
(OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 
(OCH(CHOH)O).  13C NMR (600 MHz, D2O, δ) 10.9 (NHCH2CH2CH3), 20.0 (NHCH2CH2CH3), 
31.3-49.0 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH3), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)).  
Alg5-SPER: 1H NMR (600 MHz, D2O, δ) 1.13 (NHCH2(CH2)2CH2NH), 1.56 
(NHCH2CH2CH2NH), 1.80 (C(O)NHCH2CH2CH2NH), 2.20-2.40 (CH2CH2CH2NH, 
NHCH2(CH2)2CH2NH, NHCH2CH2CH2NH2), 2.68 (NHCH2CH2CH2NH2), 2.80-3.10 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O). 13C NMR (600 MHz, 
D2O, δ) 23.2 (NHCH2(CH2)2CH2NH), 34.8-45.0 (C(O)NHCH2CH2CH2NH), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)). 
Alg5-PAPA-DPTA: 1H NMR (600 MHz, D2O, δ) 0.70-0.80 (NHCH2CH2CH3), 1.48 
(NHCH2CH2CH3), 1.50-1.70 (CH2CH2CH2NHCH2CH2CH2NH2), 2.30-2.40 
(CH2CH2CH2NHCH2CH2CH2NH2), 2.10 (CH2CH2CH2NHCH2CH2CH3), 2.60-3.10 
(CH2CH2CH2NHCH2CH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O). 13C NMR (600 MHz, 
D2O, δ) 9.4 (NHCH2CH2CH3), 20.0 (NHCH2CH2CH3), 26.9-29.5 (C(O)NHCH2CH2CH2NH, 
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NHCH2CH2CH2NH2), 31.3-49.0 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH3), 37.6-46.0 CH2 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)).  
3.2.5 Synthesis of tosylated-aminoethyl Schiff base (TES) 
The aminoethyl Schiff base was first synthesized following a 1:1 molar ratio reaction 
between ethanolamine and p-anisaldehyde for 24 h with strong continuous stirring (Figure 3.1A). 
The resulting viscous yellow solution was then placed under vacuo to pull off excess water. The 
aminoethyl Schiff base was subsequently functionalized with a tosyl group. A 1.411 g aliquot of 
the viscous solution was added in a solution of dichloromethane (5 mL) and pyridine (1.3 mL) 
with vigorous stirring. The solution was placed in an ice bath and allowed to cool to 0 °C. Tosyl 
chloride (2.0 g) was dissolved in dichloromethane (10 mL) before adding dropwise to the Schiff 
base mixture. The reaction was allowed to proceed for 24 h. The product was then precipitated in 
diethyl ether and collected via vacuum filtration to yield a yellow powder. 1H NMR (600 MHz, 
DMSO-d6, δ) 2.40-2.50 (CH3C(CHCH)CS), 3.30-3.60 (OCH2CH2N), 3.70 






3.2.6 Synthesis of ethylamine-modified chitosan oligosaccharides (COS-EA) 
Water-soluble chitosan oligosaccharides were modified with the aminoethyl Schiff base 
functional group through a tosylate nucleophilic substitution (Figure 3.1B). Briefly, COS (500 mg) 
was dissolved in 10 mL water and placed in an oil bath at 80⁰C. The tosylated-aminoethyl Schiff 









Figure 3.1 (A) Synthesis of tosyl-modified ethanolamine Schiff base. (B) Synthesis of 
ethanolamine-modified chitosan oligosaccharides. 
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the chitosan solution. After 1 h, HCl (2 mL; 5 M) was added to the reaction solution. After 18 h, 
the solution was neutralized with 1 M NaOH before product isolation via precipitation in ethanol, 
collected via centrifugation, and washed twice with ethanol to yield a brown powder. 1H NMR 
(600 MHz, D2O, δ) 1.90 (CHNHC(O)CH3), 2.30-2.90 (CHNHCH2CH2NH2), 3.30-4.00 
(OCH(CH2OH)CHCH(OH)CH(NH)), 4.40 (OCH(CHNH)O). 
3.2.7 Synthesis of N-diazeniumdiolate-modified biopolymers 
Nitric oxide-releasing alginates and chitosan oligosaccharides were synthesized as 
previously reported.10,25Polyamine-modified alginate (45 mg) was dissolved in 50 mM NaOH 
solution (3 mL) in a 1-dram glass vial. For the chitosan oligosaccharide sample, COS-EA (45 mg) 
was dissolved in mixture of water (450 µL), methanol (2.55 mL), and sodium methoxide (5.4 mM 
in methanol, 75 µL). The open vials were placed in a stainless steel reactor, and solutions stirred 
continuously via magnetic stirring. Oxygen was removed from the vessel by purging with argon 
(10 s, 7 bar) three times, followed by three additional long purges with argon (10 min, 7 bar). The 
vessel was then pressurized to 10 bar with NO gas and allowed to react for 3 d. Afterward, the 
same argon purging protocol was repeated to remove unreacted NO. The NO-releasing alginates 
were then precipitated in ethanol, collected by centrifugation, dried overnight in vacuo, and stored 
at -20 °C as a white powder. The NO-releasing COS was collected in acetone via centrifugation 
and stored similarly as a brown powder. 
3.2.8 Characterization of nitric oxide release 
Nitric oxide release was evaluated in real-time using a Sievers 280i Chemiluminescence 
NO analyzer (NOA; Boulder, CO). Measurements were taken before each use to ensure sample 
stability. Prior to analysis, the NOA was calibrated with air passed through a NO zero filter (0 ppm 
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NO) and 25.87 ppm of a NO standard gas (balance N2). In a typical measurement, the NO-releasing 
biopolymer (1 mg) was dissolved in 30 mL of PBS (10 mM, pH 6.5, 37 °C). Nitrogen was passed 
through the solution at a flow rate of 70 mL/min to carry the liberated NO from the biopolymer to 
the analyzer. Additional nitrogen flow was supplied to the flask to match the collection rate of the 
instrument (200 mL/min) to ensure that water soluble interferents (e.g., nitrite and nitrate) that may 
be present in the sample flask are not transferred to the reaction cell. Nitric oxide analysis was 
terminated when NO levels fell to below 10 ppb of NO/mg of biopolymer (the limit of detection 
of the instrument).36,37 
3.2.9 Preparation of mucus sample 
Human bronchial epithelial cell culture washings containing mucus were collected from 
excess surgical tissue (sourced from UNC-Chapel Hill Tissue Core facility). Briefly, primary HBE 
cells were grown on 0.4 µm pore-sized Millicell cell culture inserts (Millipore; Bedford, MA) 
coated with collagen in air-liquid interface media (UNC Chapel Hill-Tissue Core Facility) for a 
minimum of 6 w until the cultures developed cilia, well-defined periciliary liquid (PCL), and 
mucus layers.38 Mucus was harvested from the cell cultures following previously published 
protocols.39,40 Washings were pooled in 3,500 kDa cut off dialysis tubing (Fisher Scientific; 
Fairlawn, NJ) and concentrated against Spectra/Gel (Spectrum Labs; Rancho Dominguez, CA)  to 
3 wt% solids, which served as the minimum mucus concentration for a disease state model.40 






3.2.10 Parallel plate rheology 
 Concentrated solutions of both control (non-NO-releasing) and NO-releasing biopolymer 
samples (5 µL) were added to 50 µL aliquots of 3 wt% HBE mucus to achieve a final concentration 
of 20 mg/mL prior to collecting rheological data. Mucus samples were slowly rotated at room 
temperature for 18 h. The rheological properties of both treated and untreated (blank) mucus 
samples were measured via amplitude sweep experiments over a stress range of 0.025-50 Pa at a 
single frequency (1 Hz) using the rheometer equipped with a 20 mm diameter parallel plate set to 
a gap thickness of 50 mm. Rheological measurements were performed at 23 °C to minimize sample 
dehydration. The elastic modulus (G’) and viscous modulus (G”) were determined from the linear 
regimes as previously reported.41 
A time-based study with control and NO-releasing biopolymers was conducted following 
the aforementioned protocol. Rheological data were collected at 1 h, 3 h, and 5 h timepoints using 
the same parameters. Similarly, a nitric oxide dose-dependence study (20-80 mg/mL) using control 
and NO-releasing Alg5-PAPA-DPTA, COS-EA, and N-acetyl cysteine (1-200 mg/mL) was also 
carried out following the same protocol. 
3.2.11 Statistical analysis 
All values either numerically or with error bars are reported as the mean ± standard 
deviation of the mean for a minimum of three or more pooled experiments. Statistical significance 





3.3 Results and Discussion  
3.3.1 Synthesis of N-diazeniumdiolate-modified biopolymers 
Alginate oligosaccharides (~5 kDa) with different secondary amine functional groups (i.e., 
DETA, DPTA, PAPA, and SPER) were prepared via EDC/NHS reactions as reported previously.25 
The alkyl amine modification was confirmed via 13C NMR by the appearance of the amide bond 
peak (~160 ppm; Figure 3.2). The nitrogen content for the alkyl amine-modified materials also 
increased from 0 to 6-11%, providing further evidence of successful modification (Table 3.2).25 
The protonated amines at pH 6.5 (Table 3.2) resulted in a positive shift of the zeta potential (from 
-40 mV to between -12 to -30 mV), making the alkyl amine-modified alginates less negatively 
charged than the native alginate biopolymer.  
In addition to the monosubstituted polymer, a hybrid system was also prepared to design 
NO-releasing alginate system with potentially high initial NO flux and more sustained NO release 
by making use of NO donors having both fast and slow NO-release properties. Specifically, the 
PAPA and DPTA polyamine modifications were selected for the hybrid system based on the 
reported NO-release half-lives of the small molecule alkyl amines (0.2 and 3.0 h, respectively).42 
Integration of the peak related to the methyl terminal group of PAPA indicated that the alginate 
was 43% modified with this functional group. The percent DPTA modification for the hybrid 
alginate system (50%) was extrapolated from the total nitrogen content of the modified alginate 
biopolymer, subtracting out the predicted nitrogen contribution from PAPA (calculations provided 
in Appendix A). These percentages suggest that the two-alkyl amine functional groups have 
similar alginate modification efficiencies.  
The secondary amine-modified alginates were subsequently functionalized with NO 


















diazeniumdiolate NO donors was confirmed by UV-vis spectroscopy and the appearance of a 
characteristic absorbance band at 253 nm. 16 The resulting N-diazeniumdiolate-modified alginates 
possessed a broad range of NO payloads and release kinetics (Table 3.3), with Alg5-PAPA/NO 
and Alg5-DETA/NO having the fastest and shortest NO-release half-lives (0.1 and 2.0 h, 
respectively). Overall, the NO payloads were comparable to that of previously reported water-
soluble systems (0.3-0.6 µmol/mg; Table 3.3).10,11,25,43–45 While the alginate hybrid system (Alg5-
PAPA-DPTA/NO) had a similar NO payload to that of Alg5-PAPA/NO, both the NO-release half-
lives and durations resembled Alg5-DPTA/NO. This result was unexpected given the greater 
number of secondary amine groups for the hybrid system. It is likely that steric hindrance from the 
crowded functional groups limits N-diazeniumdiolate formation. 
The NO-release properties of the anionic alginate biopolymers were also compared to 
chitosan, another naturally derived biopolymer, comprised of repeating units of N-
acetylglucosamine and d-glucosamine units. To date, chitosan has been used for many biomedical 
drug delivery applications due to its tolerability (i.e., biocompatibility) and mucoadhesive 
properties.10,11,44–47 Lu et al. reported on the synthesis of low molecular weight (~5 kDa) NO-
releasing chitosan oligosaccharides (COS).10  A similar protocol was adopted in this work to 
prepare water soluble starting material. The COS primary amines were then modified with 
ethanolamine via a tosylate nucleophilic substitution reaction (Figure 3.1) to yield secondary 
amines that could subsequently be functionalized with NO. The resulting NO-donor-modified 
COS was found to have greater NO payloads than the alginate systems (~0.7 µmol/mg) but 
comparable NO-release kinetics (t1/2 ~ 0.8 h). The lower NO payloads for alginate compared to 
chitosan may be due to the conformation adapted by alginate’s monomers. The repeating units of 














Table 3.3 Nitric oxide-release properties of N-diazeniumdiolate-functionalized biopolymers 






t1/2 d  
(h) 
td e  
(h) 
Alg5-DETA/NO 0.34 ± 0.15 570 ± 23 2.40 ± 1.37 16.1 ± 3.5 
Alg5-DPTA/NO 0.40 ± 0.02 1000 ± 230 2.37 ± 0.10 4.4 ± 0.4 
Alg5-SPER/NO 0.39 ± 0.04 2900 ± 330 0.29 ± 0.13 3.0 ± 0.8 
Alg5-PAPA/NO 0.57 ± 0.02 11900 ± 3900 0.13 ± 0.06 2.9 ± 0.3 
Alg5-PAPA-DPTA/NO 0.53 ± 0.05 4900 ± 1300 0.30 ± 0.08 4.5 ± 1.3 
COS-EA/NO 0.74 ± 0.07 1500 ± 300 0.82 ± 0.01 10.2 ± 1.5 
aError represents standard deviation for n ≥ 3 experiments. bTotal NO released. cMaximum 
instantaneous flux of NO release. dNO-release half-life. eDuration of NO release. All 




shaped hole while the repeating units of M monomers are described as an extended ribbon, similar 
to that of chitosan. 48,49 Both monomeric units can be modified with alkyl amine functional groups 
via carbodiimide chemistry, however, the conformation adapted by G residues could limit NO 
donor formation due to steric hindrance. 
3.3.2 Effect of molecular weight on alginate-treated mucus rheology. 
The diffusion of therapeutic agents through mucus depends on both the size and the 
mucoadhesive properties of the material.4 Regardless of charge, low molecular weight polymers 
(< 10 kDa) usually diffuse through the mucus layer, allowing for more efficient drug delivery to 
the site of interest (e.g., biofilms embedded in the mucus).50 In contrast, larger molecular weight 
polymers (≥10 kDa) have increased interactions with mucins (e.g., chain entanglements, increased 
H-bonding interactions). These interactions form mucin-polymer aggregates and increase the 
viscoelastic properties of the mucus.46,50 To study the impact of alginate molecular weight on the 
viscoelasticity of mucus, the elastic (G’) and viscous (G”) moduli were measured using parallel 
plate rheology. Mucus was treated with to 20 mg/mL of bare (unmodified) alginate systems of 
different molecular weights (1, 5, 10, and 300 kDa) for 24 h. The alginate-treated samples reduced 
both the elastic and viscous moduli of mucus relative to the untreated blanks (Figure 3.3), with < 
5 kDa MW alginates reducing both elasticity and viscosity by 60-70% (Table 3.4 In agreement 
with previous studies,28,31–33 the lower molecular weight materials (Alg1 and Alg5) proved to be 
the most effective at reducing the viscoelastic properties of the mucus. Alg300 (i.e., the high 
molecular weight biopolymer)  was the least effective, as might have been expected based on 
size.28,31–33 Alginate molecular weight is a crucial factor that controls the biopolymer’s gel-forming 
ability.29,30,49 While the Alg300 system still reduced rheological properties, lower molecular 












Figure 3.3 Elastic and viscous moduli of 3 wt% human bronchial epithelial (HBE) mucus 
following treatment with 20 mg/mL Alg300 (black solid), Alg10 (black diagonal), Alg5 (gray 
solid), and Alg1 (gray diagonal). Single asterisks (*) indicate significant differences (p < 0.05) 













Table 3.4 Reduction in elastic and viscous modulus with respect to untreated 3 wt % HBE 
mucus after treatment for 24 h.a 
Scaffold 
% reduction in Elastic 
Modulusb 
% reduction in Viscous 
Modulusb 
Alg300 54 ± 4 26 ± 6 
Alg10 51 ± 13 42 ± 14 
Alg5 73 ± 15 64 ± 21 
Alg5-DETA 13 ± 2 14 ± 5 
Alg5-DPTA -8 ± 1 -7 ± 4 
Alg5-PAPA-DPTA 14 ± 1 12 ± 1 
Alg5-PAPA 14 ± 4 8 ± 3 
Alg5-SPER -17 ± 4 -43 ± 10 
Alg1 71 ± 10 77 ± 23 
COS 3 ± 1 -49 ± 4 
COS-EA -48 ± 20 -61 ± 40 
aError represents standard deviation for n ≥ 3 experiments. bReduction in both elastic and 
viscous moduli were calculated from G’ (Pa) and G” (Pa) measured at 10 rad compared to 





monomer units and reactive functional groups that would interact with the glycoprotein (Table 
3.4).31  
3.3.3 Effect of varying functional group and biopolymer charge on mucus. 
In addition to size and chain entanglement, the mucoadhesivity of the biopolymer 
(impacted most directly by the electrostatic interactions between charged pendant chains of mucins 
and the polymers) will clearly influence drug diffusion through the mucus layer.51 Positively 
charged biopolymers, including chitosan, are generally mucoadhesive, an advantageous property 
for facilitating localized drug delivery to mucus-coated regions as in the lungs.52–55 However, 
studies have also shown that increased mucoadhesivity may promote the formation of polymer-
mucin aggregates that, in turn, increase the viscoelastic properties of the mucus layer and limit 
drug diffusion.53 Neutral and negatively charged polymers (e.g., polyethylene glycol, alginate) 
reported to exhibit mucus layer penetration are being considered as alternatives for drug delivery 
in mucus coated regions.32,50,53 Amine modification on alginate imparts a positive charge on the 
biopolymer that could influence its mucoadhesive property. Thus, the impact of these functional 
groups on the elastic and viscous properties of the mucus might prove equally relevant. 
The effect of biopolymer charge was studied after modifying Alg5 with different alkyl 
amine functional groups (i.e., DETA, DPTA, PAPA, and SPER). The Alg5 systems were selected 
for this study to allow for a direct comparison with the previously developed NO-releasing 
chitosan biopolymers with a similar molecular weight. As expected, modification of the alginate 
backbone with alkyl amine functional groups resulted in a distinct positive charge (Table 3.2), 
although increases noted in the viscoelastic properties of mucus treated with amine-modified 





Figure 3.4 Elastic and viscous moduli of 3 wt% human bronchial epithelial (HBE) mucus 
following treatment with 20 mg/mL unmodified (solid), modified (horizontal stripe), and NO-
releasing (diagonal stripe) (A) Alg5-DETA, (B) Alg5-DPTA, (C) Alg5-PAPA, (D) Alg5-
SPER, (E) Alg5-PAPA-DPTA, and (F) COS-EA. Values presented as the mean standard error 
of the mean for n = 3 experiments. Asterisks (*) indicate significant differences (p < 0.05) 

















Table 3.5 Nitric oxide dose and corresponding reduction in elastic and viscous moduli of 3 





% reduction in 
Elastic 
Modulusc 
% reduction in 
Viscous 
Modulusc 
Alg5-DETA/NO 8 ± 3 45 ± 13 45 ± 8 
Alg5-DPTA/NO 8 ± 2 48 ± 10 46 ± 6 
Alg5-PAPA-DPTA/NO 11 ± 1 60 ± 7 57 ± 10 
Alg5-PAPA/NO 11 ± 0 34 ± 4 22 ± 4 
Alg5-SPER/NO 8 ± 1 36 ± 7 28 ± 8 
COS-EA/NO 15 ± 1 -11 ± 4 -61 ± 26 
aEach parameter was determined from multiple replicates (n ≥ 3). bNO dose calculated from 
NO totals in PBS (10 mM, pH 6.5). cReduction in both elastic and viscous moduli were 








amine-modified alginates with a less negative zeta potential (e.g., Alg5-SPER) increased both the 
mucus elasticity and viscosity (~17 and 43%, respectively; Figure 3.4 and Table 3.4). Negligible 
changes to the mucus was observed with more negatively charged alginate (i.e., Alg5-PAPA)  
compared to the reductive effect of the unmodified biopolymer. The increase in both elasticity and 
viscosity for Alg5-SPER, Alg5-DPTA, Alg5-DETA biopolymers suggests that the addition of 
amine-based chemical modification resulting in cationic ammonium groups at physiological pH, 
facilitates interaction with the net negatively charged mucin glycoproteins via electrostatic 
interactions.4,56   
Treatment of mucus with the NO-releasing biopolymers resulted in a decrease in both the 
elastic (~30-60%) and viscous (~20-60%) moduli, with reductive ability dependent on the NO 
donor (Table 3.5). Of the different alginate modifications, the hybrid Alg5-PAPA-DPTA/NO 
biopolymer resulted in the greatest reduction among the different alginate systems (~60% for both 
elastic and viscous moduli). The enhanced action of the hybrid alginate biopolymers suggests 
thatthe mucolytic ability of the alginates depends on both the NO payloads and the NO-release 
kinetics, with higher NO totals and slower release resulting in greater reduction in the elastic and 
viscous moduli. While addition of the secondary amine-bearing functional groups counteracts the 
effect of the alginate biopolymer, the NO release and NO’s mucolytic activity influences the mucus 
to the greatest extent. As such, the results suggest the potential of using alginate biopolymers as 
an attractive biopolymer for NO storage and delivery through the mucus-coated airways.    
Relative to unmodified Alg5, native COS did not significantly change mucus rheology 
(Figure 3.4). However, the elasticity and viscosity of mucus treated with COS-EA increased by 
~40 and 60%, respectively (Table 3.4). These results re-emphasize the effect of biopolymer charge 
on mucus rheology.  In contrast, NO-releasing chitosan decreased both the elastic and viscous 
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moduli to that of the mucus treated with the unmodified COS.  Similarly, Reighard et al. reported 
a reduction in the size of mucin multimers after treatment with NO-releasing COS compared to 
treatment with blank buffer or COS controls (non-NO-releasing).20  
While the results of this study indicate that NO has potential as a mucolytic agent, the 
charge of the delivery system may further influence mucus rheology. Interactions between the 
biopolymer and mucin glycoproteins can enhance NO delivery, as reported for mucoadhesive 
COS.20  However, electrostatic interactions between highly charged biopolymers and mucin might 
facilitate unfavorable results (i.e., greater viscoelasticity). For NO-releasing therapeutics, the 
positive charge of the secondary amine-modified biopolymer has the potential to mitigate NO’s 
effect as a mucolytic by promoting the formation of chitosan-mucin aggregates. The use of a net 
negatively charged biopolymer, such as alginate, may more favorably act on mucus to improve 
mucociliary clearance in diseased airways. Of course, such hypothesis must be further evaluated 
pre-clinically and clinically in human trials. 
3.3.4 Effect of nitric oxide-release kinetics 
Previous reports demonstrated the importance of NO-release kinetics on the antibacterial 
activity of macromolecular NO-release systems.22–25 For example, slow and sustained NO-
releasing alginate oligosaccharides were proved most favorable for eradicating bacterial biofilms 
at low (≤8 mg/mL) biopolymer concentrations.25 In a similar  mode, NO’s ability to alter mucus 
may also depend on NO-release kinetics. To evaluate this hypothesis, mucus samples were treated 
with equal concentrations (20 mg/mL) of. Alg5-DPTA, Alg5-PAPA-DPTA, and Alg5-PAPA 
biopolymers, selected based on their diverse NO-release kinetics. 
As anticipated, the secondary amine-modified oligosaccharides did not alter the 









Figure 3.5 Elastic and viscous moduli of 3 wt% HBE mucus following treatment with (A) 
COS-EA, (B) Alg5-DPTA, (C) Alg5-PAPA, and (D) Alg5-PAPA-DPTA after 1 hour (black 
solid), 3 hours (black diagonal), 5 hours (gray solid), and 24 hours (gray diagonal) exposure. 










Figure 3.6 Elastic and viscous moduli of 3 wt% HBE mucus following treatment with (A) 
COS-EA/NO, (B) Alg5-DPTA/NO, (C) Alg5-PAPA/NO, and (D) Alg5-PAPA-DPTA/NO 
after 1 hour (black solid), 3 hours (black diagonal), 5 hours (gray solid), and 24 hours (gray 
diagonal) exposure. Asterisks (*) indicate significant differences (p < 0.05) relative to 







only exception. Treatment with COS-EA resulted in an increase in the elastic and viscous moduli 
starting at 1 h (Figure 3.5). The mucus viscoelasticity remained constant even upon treatment with 
COS-EA/NO, regardless of the exposure time (Figure 3.6), suggesting that treatment with COS-
EA/NO has no overall impact on mucus rheology.  
The greatest initial reductions in both elasticity and viscosity were observed after 1 h 
following treatment with the Alg5-PAPA/NO and Alg5-PAPA-DPTA/NO biopolymers (60- 70% 
and 70-80%, respectively). The large initial NO fluxes characteristic of these materials compared 
to the slower NO-releasing biopolymers (i.e., Alg5-DPTA/NO and COS-EA/NO), induced 
mucolysis via delivery of a large NO dose (Table 3.3). However, the faster NO-releasing system 
(Alg5-PAPA/NO, half-life ~0.1 h) had a depleted NO payload (i.e., NO levels were below the 
limit of detection of the NOA) at longer exposure times (e.g., 3 and 5 h post exposure), causing 
the mucus viscoelasticity to return to pre-treatment levels. The biopolymers remained in the mucus 
sample without NO release capacity with potential for charge-based mucus interactions facilitated 
by the positively charged Alg5-PAPA and the negatively charged residues of mucin 
glycoproteins.4,56 
In contrast, samples treated with Alg5-PAPA-DPTA/NO did not significantly vary across 
treatment exposure periods (Figure 3.6). The slower NO-release properties of the hybrid alginate 
biopolymer enabled by the DPTA modification allowed for near continuous NO release through 5 
h (Table 3.3). Even after 24 h, when NO was depleted, the rheological properties of the mucus 
were comparable to that observed at 1 h, resulting in a significant reduction in viscoelasticity 
compared to the non-NO-releasing control. Similarly, the slower sustained NO release from Alg5-
DPTA/NO (half-life ~0.4 h) maintained the initial reduction in elasticity and viscosity (~50 and 
60%, respectively) over the course of the experiment (Figure 3.6). Similar to the controls, no 
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additional changes were observed up to 24 h once Alg5-DPTA/NO and Alg5-PAPA-DPTA/NO 
were both depleted of NO. For both Alg5-PAPA-DPTA/NO and Alg5-DPTA/NO, two competing 
mechanisms occur as NO is released by the biopolymer. Electrostatic interactions between amine 
groups of the modified alginates can potentially interact with the mucins over the treatment period. 
However, the release of NO is steady over this same period, thereby acting as a mucolytic. Overall, 
these results suggest that while a large initial NO flux is favorable for greater reduction in mucus 
viscoelasticity, slower and more sustained NO release is required to maintain a mucolytic effect 
over extended exposure periods. 
3.3.5 Dose-dependent effects 
A range of concentrations using both control and NO-releasing biopolymers were used to 
treat mucus samples to evaluate dosing effects. The alginate system selected for this study was 
Alg5-PAPA-DPTA due to its ability to greatly reduce mucus rheology. For comparison, we also 
evaluated COS-EA at varying concentrations.   
Both control and NO-releasing Alg5-PAPA-DPTA biopolymers reduced the rheological 
moduli of mucus linearly as a function of concentration (Figure 3.7). At the lowest concentration 
tested (20 mg/mL), Alg5-PAPA-DPTA/NO was able to achieve a greater reduction in elasticity 
and viscosity (60 and 80 %, respectively) compared to the Alg5-PAPA-DPTA control (~10% for 
both elastic and viscous moduli), clearly demonstrating the enhanced mucolytic activity with NO. 
At the greatest concentration (80 mg/mL), the control biopolymer reduced the elasticity and 
viscosity up to 90 and 80%. The NO-releasing form was able to further decrease these moduli 
nearly 100%, suggesting an additive effect between the biopolymer and NO for the alginate system 








Figure 3.7 Elastic (circle) and viscous (square) moduli of 3 wt% HBE mucus following 
treatment with 20, 40, 60, and 80 mg/mL concentrations of control (hollow) and NO-releasing 




Treatment of mucus with COS-EA controls showed an increase in both elasticity and viscosity 
from 20-40 mg/mL, but then less effect above 40 mg/mL (Figure 3.7). Previous reports have 
indicated that COS concentrations above 4.5 mg/mg mucin (i.e., the COS to mucin ratio at 40 
mg/mL) lead to disaggregated chitosan-mucin complexes.20,46 Imparting NO-release capabilities 
minimized the impact of chitosan’s attractive interaction with mucus at lower concentrations (i.e., 
20-40 mg/mL). At concentrations greater than 40 mg/mL, the NO-releasing COS-EA reduced the 
mucus elasticity and viscosity up to 70 and 80%, respectively (Figure 3.7). These results suggest 
that at larger COS-EA/NO concentrations, NO overcomes the electrostatic effects between the 
positively charged chitosan biopolymer and negatively charged mucin glycoproteins, resulting in 
a therapeutic action similar to that of the NO-releasing alginate systems. Regardless, the additive 
effect of the alginate biopolymer with NO at increasing doses, combined with the lower 
concentrations required to achieve substantial reduction in mucus rheology demonstrates an 
advantage for NO-releasing alginates over chitosan oligosaccharides with respect to mucolytic 
action. 
3.3.6 Efficacy compared to N-acetyl cysteine (NAC) 
While the mucolytic action of NO-releasing alginate materials was demonstrated, a 
comparison of relative efficacy with conventional mucolytic drugs such as N-acetylcysteine 
(NAC) is necessary to fully evaluate its potential as a therapeutic.57–60   For this work, the effect 
of NAC on mucus rheology was evaluated at comparable doses to the lowest NO dose delivered 
by the oligosaccharide biopolymers (1-2 mg/mL or 8-16 µmol/mL NAC) and currently nebulized 
therapeutic doses (100-200 mg/mL or 613-1220 µmol/mL NAC).57,58,60 At equivalent doses to NO, 
NAC reduced the mucus elasticity by ~2-8%,  which is minimal compared to that observed using 













Table 3.6 Reduction in elastic and viscous moduli of 3 wt % HBE mucus after treatment 




% reduction in 
Elastic Modulusb 
% reduction in 
Viscous Modulusb 
NAC 0.1 wt% 8  2 ± 1 2 ± 1 
NAC 0.2 wt % 16 8 ± 2 -23 ± 7 
NAC 10 wt % 613 41 ± 3 -39 ± 4  
NAC 20 wt % 1220 44 ± 4 -38 ± 12  
aEach parameter was determined from multiple replicates (n ≥ 3). bReduction in both elastic 
and viscous moduli were calculated from G’ (Pa) and G” (Pa) measured at 10 rad compared 















Figure 3.8 Elastic and viscous moduli of 3 wt% HBE mucus following treatment with NAC 
at 0.1 wt% (black solid), 0.2 wt % (black diagonal), 10 wt % (gray solid), and 20 wt% (gray 
diagonal).  Values presented as the mean standard error of the mean for n = 3 experiments. 





of NAC, the small molecule mucolytic reduced mucus elasticity at an equivalent level to the lowest 
concentration of alginate (~40%) but at the expense of increasing viscosity (Figure 3.8). As a 
mucolytic, NAC reduces disulfide bonds of high molecular weight mucins (resulting in sulfhydryl 
groups).61,62 We hypothesize that the thiol-bearing small molecule at high concentrations may 
cause undesirable entanglement within the mucin network through interactions with the mucin 
disulfide bonds (i.e., inducing both inter- and intra- mucin disulfide bond formation), resulting in 
greater viscosity over the 24-h exposure period.4,56 Despite an overall positive effect on mucus 
viscoelasticity (Figure A5), the result of this study indicates that above a threshold NAC 
concentration, the mucolytic action becomes limited (i.e., increased viscosity despite decreasing 
elasticity), leading to no discernable change with respect to the untreated sample. The opposite 
appears true for the NO-releasing alginates. Indeed, the mucolytic action of both control and NO-
releasing alginate is dose dependent. Moreover, lower NO-releasing alginate concentrations are 
needed to exhibit the same reductive effect as that of high concentrations of NAC. Combined with 
the previously reported antibacterial properties of the NO-releasing alginates,25 the results of this 
study highlight the potential utility of these materials as dual-action therapeutic agents for the 
treatment of chronic respiratory diseases such as cystic fibrosis. 
 
3.4 Conclusions 
Low molecular weight (5 kDa) alginate oligosaccharides having high initial NO fluxes and 
sustained NO-release (e.g., Alg5-PAPA-DPTA/NO) greatly reduced both the elasticity and 
viscosity of mucus, suggesting a high potential utility for improving mucociliary clearance in 
diseased lungs. Regardless of chemical modifications, each alginate biopolymer investigated was 
more efficacious relative to the cationic biopolymer chitosan, indicating that a negatively charged 
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scaffold is beneficial for reducing mucus viscoelasticity. As the NO-releasing dose of the alginate 
oligosaccharides required is even lower than that of current standard of care mucolytic agents 
(NAC) and the levels of NO released are antibacterial,24 this work highlights the utility of NO- 
releasing alginates as a highly unique therapeutic agent for treating chronic respiratory diseases 
such as cystic fibrosis. While the exact mechanism through which NO alters the rheological 
properties is yet to be elucidated, the results present herein suggest the addition of NO increases 
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CHAPTER 4: ANTIBIOFILM EFFICACY OF NITRIC OXIDE-RELEASING ALGINATES 
AGAINST CYSTIC FIBROSIS BACTERIAL PATHOGENS 
4.1 Introduction 
 Cystic fibrosis (CF) is an autosomal disease caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene. These mutations cause a deficiency in 
chloride secretion from the epithelial cells in the airways and ultimately interfere with the 
mucociliary clearance of inhaled microorganisms.1,2 As a result, a thick stagnant mucus layer 
accumulates, obstructing airways in the CF lung. Nutrients in the mucus foster a suitable 
environment for the colonization of bacterial pathogens. As the mucus layer thickens, it protects 
the bacteria from antibiotic treatments.3,4 Bacterial biofilms are cooperative communities of 
bacteria encapsulated by a self-secreted exopolysaccharide matrix that provides additional 
protection from the host immune response and antibiotics. These combined protective mechanisms 
further complicate efforts to eradicate pathogens, even in the age of antibiotics.3,4 Additionally, 
the efficacy of antibiotics are minimized by the altered microenvironments in biofilms (e.g., lower 
oxygen concentrations, nutrient depletion) and slower bacterial metabolism.5–9 Persistent 
colonization of multiple pathogens, including Pseudomonas aeruginosa, Burkholderia cepacia 
complex (BCC), Staphylococcus aureus, and methicillin-resistant S. aureus (MRSA), elicits a 
chronic inflammatory response that ultimately degrade lung function to the point of respiratory 
failure.9–12 The need for non-conventional antibacterial agents to eradicate biofilm-based bacteria 
is great.13–15    
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Nitric oxide (NO) is an endogenously produced broad-spectrum antibacterial free radical 
capable of eradicating both planktonic bacteria and biofilms. Nitric oxide and its reactive 
byproducts (e.g., peroxynitrite and dinitrogen trioxide) chemically alter bacterial proteins, DNA, 
and metabolic enzymes, disrupting vital cellular functions and structures to induce killing.16–19 
While early studies demonstrated the efficacy of NO as an antibacterial agent via direct gaseous 
administration, the therapeutic utility of inhaled gas is limited by NO’s high reactivity and short 
lifetime in biological media, and the hazards associated with high pressure gas cylinders.17 The 
use of NO donors (e.g., N-diazeniumdiolates) for NO storage and triggered release under 
physiological conditions (pH 7.4, 37 °C) is an alternative to direct inhalation.16,17 N-
diazeniumdiolates undergo proton-initiated decomposition, with NO-release kinetics controlled by 
factors such as pH, temperature, and the chemical structure of the precursor amine. Unfortunately, 
the utility of small molecule N-diazeniumdiolate NO donors is limited by the toxicity of the 
precursor structure when larger NO payloads are required.16,17,20 This shortcoming has been 
addressed through the development of macromolecular scaffolds with tunable NO release 
capabilities. These NO donors facilitate better control over NO-release kinetics and enhanced 
bacterial killing (i.e., require lower scaffold concentrations).16,17,20,21 
 Inhalation of NO-releasing macromolecular biopolymers may represent an attractive 
therapeutic strategy because of extended NO release durations (i.e., several hours), allowing for 
expanded NO delivery via intermittent (once or twice daily) treatment. Alginate, a biopolymer 
composed of 1,4-linked α-l-guluronic acid (G) and β-d-mannuronic acid (M) units,22–24 holds 
particular promise as a macromolecular NO donor system for inhalation applications due to its 
favorable biocompatibility and unprecedented water solubility.22,25–28 Recent studies have 
demonstrated the ability of low molecular weight alginate oligosaccharides to potentiate the 
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antibacterial efficacy of conventional antibiotics by altering biofilm morphology and mucin 
assembly, reducing mucus viscoelasticity and enhancing (antibiotic) delivery.23,29–31  
 Herein, we report on the antibiofilm action of NO-releasing alginate oligosaccharides 
against multiple CF-relevant pathogens.10,32–34 Selection of specific NO donor precursors to 
modify the alginate allowed for tunable NO-release properties (e.g., total NO payload, NO-release 
half-lives).35–37 As pathogens are able to genetically adapt to the hypoxic or anaerobic conditions 
in the CF lung microenvironment, allowing it to develop resistance against conventionally used 
antibiotics, the efficacy of the NO-releasing alginates were tested against biofilms grown under 
aerobic (with oxygen) and anaerobic (little to no oxygen) conditions.4 The effect of NO release on 
antibacterial action was examined as a function of alginate biopolymer chemical modification. 
Bactericidal activity of the NO-releasing alginates was also compared to tobramycin and 
vancomycin, two antibiotics commonly used for the treatment of infections in CF, to assess 
therapeutic potential relative to current standard of care practice. 
  
4.2 Experimental Section 
4.2.1 Materials 
Alginic acid sodium salt from brown algae (low viscosity), bis(3-aminopropyl)amine 
(DPTA), diethylenetriamine (DETA), N-propyl-1,3-propanediamine (PAPA), spermine (SPER), 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimde 
(NHS), casamino acids, tobramycin, vancomycin hydrochloride, and pig gastric mucin (PGM) 
type II were purchased from Sigma-Aldrich (St. Louis, MO). Deoxyribonucleic acid (DNA) 
sodium salt, egg yolk enrichment, and common laboratory salts and solvents were purchased from 
Fischer Scientific (Fair Lawn, NJ). Unless otherwise specified, all chemicals were used as received 
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without further purification. Argon (Ar), carbon dioxide (CO2), nitrogen (N2), nitric oxide (NO) 
calibration (25.87 ppm balance N2), and pure NO (99.5%) gas cylinders were purchased from 
Airgas National Welders (Raleigh, NC). Distilled water was purified to a resistivity of 18.2 
MΩ•cm and a total organic content of ≤6 ppb using a Millipore Milli-Q UV Gradient A10 System 
(Bedford, MA). 
4.2.2 Bacterial strains and media 
The laboratory Pseudomonas aeruginosa strain K (PAK) and the Burkholderia cepacia 
complex (BCC) clinical strain were a gift from Matthew Wolfgang from the Department of 
Microbiology and Immunology at the University of North Carolina at Chapel Hill (Chapel Hill, 
NC). Staphylococcus aureus (ATCC #29213) and methicillin-resistant S. aureus (MRSA; ATCC 
#33591) were obtained from American Type Tissue Culture Collection (Manassas, VA). Luria-
Bertani (LB) broth and Tryptic Soy Agar (TSA) plates were obtained from Becton, Dickinson, and 
Company (Franklin Lakes, NJ). Artificial sputum media (ASM) was prepared following a 
previously published protocol.3,38 Briefly, DNA (4 g), pig gastric mucin type II (5 g), casamino 
acids (5 g), diethylenetriaminepentaacetic acid (DTPA; 5.9 mg), sodium chloride (NaCl; 5 g), and 
potassium chloride (KCl; 2.2 g) were dissolved in 800 mL of sterile water. A 5-mL aliquot of egg 
yolk emulsion was added to the resulting solution as a source of lecithin. The pH of the solution 
was adjusted to 6.5 with 1 M Tris (pH 8.5) and the volume brought up to 1 L with sterile water 
before being sterilized via filtration using Millipore Steritop filter units (Burlington, MA). The 
filtered ASM was stored in the dark at 4 °C with each stock solution used within a month. For 







1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker (600 
MHz) spectrometer. A PerkinElmer Elemental Analyzer Series 2400 Instrument (Waltham, MA) 
was used for elemental (carbon, hydrogen, and nitrogen; CHN) analysis. Zeta potential 
measurements were taken in phosphate buffer (10 mM PB; pH 6.5) using a Zetasizer Nano 
(Malvern Instruments, UK). Gel permeation chromatography (GPC) measurements were carried 
out in 0.1 M sodium nitrate (NaNO3) using an aqueous GPC system equipped with a Waters 2414 
refractive index detector (Milford, MA) coupled to a Wyatt miniDawn TREOS multi-angle light 
scattering detector (Santa Barbara, CA). 
4.2.4 Oxidative degradation of alginate 
High molecular weight alginate biopolymers were degraded to lower molecular weight 
oligosaccharides following previously published protocols.37,40 Briefly, the biopolymer (2.5 g) was 
dissolved in 15 wt% hydrogen peroxide (50 mL) and stirred in an oil bath for 1 h at 80 °C. The 
resulting solution was filtered to remove insoluble material. The alginate oligosaccharides were 
collected and washed copiously with ethanol before drying in vacuo to yield a white powder. 
4.2.5  Synthesis of polyamine-modified alginates (AlgMW-alkyl amine) 
 Monofunctional alginate materials used in this study were modified with 
diethylenetriamine (DETA), bis(3-aminopropyl)amine (DPTA), N-propyl-1,3-propanediamine 
(PAPA), or spermine (SPER) following a previously published protocol.37 Briefly, alginate (100 
mg) was dissolved in 10 mL phosphate buffered saline (PBS; 10 mM, pH 6.5) with a 2:1 molar 
ratio of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and a 2:1 molar 
ratio of N-hydroxysuccinimide (NHS) with respect to the carboxylic acid moeities of alginates. 
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The reaction was left to stir for 1 h. After 1 h, a 4:1 molar ratio of the alkyl amine with respect to 
the carboxylic acid groups of the alginates was added dropwise to the mixture. The reaction was 
allowed to proceed for 24 h at room temperature under constant stirring. The amine-modified 
alginates were precipitated in methanol and collected via centrifugation, washed twice with 
methanol, and dried in vacuo to yield a white solid for each modification. A hybrid system 
modified with PAPA and DPTA functional groups was also synthesized following the same 
procedure, with the PAPA moiety first added dropwise at a 4:1 molar ratio of the alkyl amine with 
respect to alginate carboxylic acids followed by addition of a 4:1 molar ratio of DPTA with respect 
to the same groups. The representative 1H and 13C NMR peaks for unmodified and alkyl amine-
modified alginates are listed below: 
Alg5: 1H NMR (600 MHz, D2O, δ) 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (OHCOCH), 4.90 (OCH(CHOH)O). 13C NMR (600 MHz, 
D2O, δ) 65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 175.0 
(CHC(O)). 
Alg5-DPTA: 1H NMR (600 MHz, D2O, δ) 1.60-1.80 (CH2CH2CH2NHCH2CH2CH2NH2), 2.60-
2.30 (CH2CH2CH2NHCH2CH2CH2NH2), 2.80-3.10 (CH2CH2CH2NHCH2CH2CH2NH2), 3.60-
4.05 (OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 
(OCH(CHOH)O). 13C NMR (600 MHz, D2O, δ) 26.9-29.5 (C(O)NHCH2CH2CH2NH, 
NHCH2CH2CH2NH2), 37.6-46.0 CH2 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 65.0-
80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)).  
Alg5-DETA: 1H NMR (600 MHz, D2O, δ) 2.30-3.30 (CH2CH2NHCH2CH2NH2), 3.60-4.05 
(OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 
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(OCH(CHOH)O). 13C NMR (600 MHz, D2O, δ) 39.0-47.0 (C(O)NHCH2CH2NHCH2CH2NH2), 
65.0-80.0 (OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 
175.0 (CHC(O)).  
Alg5-PAPA: 1H NMR (600 MHz, D2O, δ) 0.70-0.80 (NHCH2CH2CH3), 1.52 (NHCH2CH2CH3), 
1.85 (CH2CH2CH2NHCH2CH2CH3), 2.80-3.10 (CH2CH2CH2NHCH2CH2CH3), 3.60-4.05 
(OCHCH(OH)CH(OH)), 4.30 (OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 
(OCH(CHOH)O).  13C NMR (600 MHz, D2O, δ) 10.9 (NHCH2CH2CH3), 20.0 (NHCH2CH2CH3), 
31.3-49.0 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH3), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)).  
Alg5-SPER: 1H NMR (600 MHz, D2O, δ) 1.13 (NHCH2(CH2)2CH2NH), 1.56 
(NHCH2CH2CH2NH), 1.80 (C(O)NHCH2CH2CH2NH), 2.20-2.40 (CH2CH2CH2NH, 
NHCH2(CH2)2CH2NH, NHCH2CH2CH2NH2), 2.68 (NHCH2CH2CH2NH2), 2.80-3.10 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O). 13C NMR (600 MHz, 
D2O, δ) 23.2 (NHCH2(CH2)2CH2NH), 34.8-45.0 (C(O)NHCH2CH2CH2NH), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)). 
Alg5-PAPA-DPTA: 1H NMR (600 MHz, D2O, δ) 0.70-0.80 (NHCH2CH2CH3), 1.48 
(NHCH2CH2CH3), 1.50-1.70 (CH2CH2CH2NHCH2CH2CH2NH2), 2.30-2.40 
(CH2CH2CH2NHCH2CH2CH2NH2), 2.10 (CH2CH2CH2NHCH2CH2CH3), 2.60-3.10 
(CH2CH2CH2NHCH2CH2CH2NH2), 3.60-4.05 (OCHCH(OH)CH(OH)), 4.30 
(OCHCH(OH)CH(OH), 4.50-4.60 (NHCOCH), 4.90 (OCH(CHOH)O). 13C NMR (600 MHz, 
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D2O, δ) 9.4 (NHCH2CH2CH3), 20.0 (NHCH2CH2CH3), 26.9-29.5 (C(O)NHCH2CH2CH2NH, 
NHCH2CH2CH2NH2), 31.3-49.0 (C(O)NHCH2CH2CH2NH, NHCH2CH2CH3), 37.6-46.0 CH2 
(C(O)NHCH2CH2CH2NH, NHCH2CH2CH2NH2), 65.0-80.0 
(OCHCH(OH)CH(OH)CH(OH)CH(O)), 100.0 (OCHCH(OH)), 160.0 (CHC(O)NH), 175.0 
(CHC(O)). 
4.2.6 Synthesis of N-diazeniumdiolate-modified alginates 
 Nitric oxide donor-modified alginates were synthesized as previously reported.37 Briefly, 
polyamine-modified alginate (45 mg) was dissolved in 50 mM NaOH solution (3 mL) in a 1-dram 
glass vial. The (open) vials were placed in a stainless steel reactor with continuous magnetic 
stirring. Oxygen was removed from the vessel by purging with argon (10 s, 7 bar) three times. The 
vessel was then pressurized to 10 bar with NO gas and allowed to react for 3 d. Afterward, the 
same argon purging protocol was repeated to remove unreacted NO. The NO-releasing alginate 
oligosaccharides were then precipitated in ethanol, collected by centrifugation, dried overnight in 
vacuo, and stored at -20 °C as a white powder. 
4.2.7 Characterization of nitric oxide release 
Nitric oxide release was evaluated in real-time using a Sievers 280i Chemiluminescence 
NO analyzer (NOA; Boulder, CO).41,42 Measurements were taken before each biofilm experiment 
to ensure sample stability. Prior to analysis, the NOA was calibrated with air passed through a NO 
zero filter (0 ppm NO) and 25.87 ppm of NO standard gas (balance N2). In a typical measurement, 
NO-releasing alginate oligosaccharide (~1 mg) was dissolved in 30 mL of either PBS (10 mM, pH 
6.5), mucin (4 wt%, pH 6.5), DNA (4 wt%, pH 6.5), or ASM (pH 6.5). Nitrogen was flowed 
through the solution at a flow rate of 70 mL/min to carry the liberated NO from the biopolymer to 
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the analyzer. Additional nitrogen flow was supplied to the flask to match the collection rate of the 
instrument (200 mL/min) to remove water soluble interferents (e.g., nitrite and nitrate).41,42 Nitric 
oxide analysis was terminated when NO levels fell below 10 ppb of NO/mg of alginate (the limit 
of detection of the instrument). 
4.2.8 Biofilm eradication assays 
P. aeruginosa, BCC, S. aureus and MRSA bacterial cultures were grown overnight in LB 
(pH 6.5) at 37 ⁰C and recultured in fresh LB to a concentration of 108 CFU/mL. These solutions 
were diluted to 106 CFU/mL in sterile media (P. aeruginosa and BCC in ASM; S. aureus and 
MRSA in ASM with 0.25% glucose) and grown for 48 h at 37 ⁰C with gentle shaking.3,38,43 
Biofilms in ASM were treated with premeasured samples of NO-releasing alginates, control 
alginates, or antibiotic (i.e., tobramycin, vancomycin) dissolved in ASM (100 µL), with final 
concentrations ranging from 2 to 64 mg/mL. Treatment was for 24 h at 37 ⁰C in either aerobic 
(with oxygen) and anaerobic (low oxygen) conditions. All anaerobic biofilm growth and exposures 
were conducted in a Coy anaerobic chamber equipped with an oxygen and hydrogen monitor (Coy 
Laboratory Products; Grass Lake, MI). For the anaerobic chamber, oxygen levels were consistently 
maintained at 0 ppm throughout the experiment. Untreated controls (blanks) were included in each 
experiment to ensure bacterial viability over the duration of the experiment. The dispersed biofilms 
were then pipetted out of the wells, serially diluted (10-, 100-, 1000-, and 10,000-fold dilutions), 
vortexed, plated on TSA plates using an Eddy Jet spiral plater (IUL; Farmingdale, NY), and 
incubated overnight at 37 °C. Bacterial viability was assessed using a Flash & Go colony counter 
(IUL; Farmingdale, NY).  The minimum biofilm eradication concentration at 24 h (MBEC24h) was 
defined as the minimum concentration required to achieve a 5-log reduction in bacterial viability 
compared to untreated cells (i.e., reduced bacterial counts from 108 to ≤103 CFU/mL). The limit 
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of detection of this method is 2.5 × 103 CFU/mL.44 The NO dose (µg NO/mL) was derived from 
the MBEC24h of the alginate samples (mg/mL) with the NO released measured in ASM (pH 6.5; 
µmol NO/mg alginate) over the testing period. 
4.2.9 Time-based biofilm eradication assay 
P. aeruginosa biofilms were grown aerobically and anaerobically, and treated with either 
Alg5-PAPA-DPTA/NO, Alg5-PAPA/NO, and Alg5-DPTA/NO (4 and 2 mg/mL, respectively) 
following the same protocol as for the biofilm eradication assays. Untreated controls were included 
to ensure bacteria viability over the duration of the experiment. The samples were incubated with 
gentle shaking at 37 °C for 2, 4, and 6 h before plating on TSA plates using an Eddy Jet spiral 
plater and incubating overnight at 37 °C. Bacterial viability was assessed using a Flash & Go 
colony counter. 
4.2.10 Statistical analysis 
All values either numerically or with error bars are reported as the mean ± standard 
deviation of the mean for a minimum of three or more pooled experiments. Statistical significance 
was determined using the two-tailed Student’s t-test. 
 
4.3 Results and Discussion  
 Alginate oligosaccharides (~5 kDa) with different secondary amine functional groups (e.g., 
DETA, DPTA, PAPA, and SPER) were prepared via EDC/NHS reactions following previously 
published protocols.37 Alkyl amine modification was confirmed via 13C NMR with the observation 
of an amide bond peak (~160 ppm) and elemental analysis (monitoring the increase in nitrogen 
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content from 0 to 6-11 wt%).37  The alkyl amine-modified systems were subsequently 
functionalized with N-diazeniumdiolates via exposure to high pressures (i.e., 10 bar) of NO in 
basic aqueous solution.37 Formation of NO donors was confirmed using UV-Vis spectroscopy and 
the appearance of a characteristic absorbance band at 253 nm.21 The resulting NO-releasing 
alginates possessed a broad range of NO-release kinetics when measured in phosphate buffered 
saline (PBS) at pH 6.5, with the PAPA- and DETA-modified alginates having the fastest (~0.1 h) 
and slowest (~2.0 h) NO-release half-lives, respectively (Table 4.1). In buffer, the biopolymers 
were characterized as having NO totals comparable to other previously reported NO-releasing 
biopolymers (0.3-0.6 µmol/mg; Table 4.1).37,45–49   
4.3.1 Nitric oxide release in biological media. 
 The NO-release properties of the alginate materials were measured in artificial sputum 
media (ASM, pH 6.5) to determine the total amount of NO available in environments that more 
closely mimic those in the CF airway.3,50–52 As expected, the NO payloads were slightly lower 
(0.2-0.3 µmol/mg) when measured in ASM compared to in PBS due to the rapid scavenging of 
NO by reactive oxygen species (ROS) and proteins in biological media (Table 4.2; Figure 4.1).39,41 
Nevertheless, a range of NO-release kinetics for the alginates was still observed in ASM, with 
Alg5-DETA/NO maintaining the longest NO-release half-life (~40 min) and Alg5-PAPA/NO the 
fastest (~4 min), following the same order observed in PBS (Table 4.1). In ASM, a decrease in the 
NO flux (i.e., maximum instantaneous amount of NO released) was observed for both Alg5-
PAPA/NO and Alg5-SPER/NO, again suggesting NO scavenging.39 In contrast, both Alg5-
DETA/NO and Alg5-DPTA/NO systems were characterized with an elevated NO flux (i.e., 
maximum instantaneous NO being released)  in media relative to buffer. Previous work has pointed 














Table 4.1 Nitric oxide-release properties of N-diazeniumdiolate-functionalized biopolymers 






t1/2 d (h) td e (h) 
Alg5-DETA/NO 0.36 ± 0.10 590 ± 20 2.40 ± 1.40 16.0 ± 3.9 
Alg5-DPTA/NO 0.42 ± 0.03 1000 ± 230 0.40 ± 0.11 4.5 ± 0.2 
Alg5-SPER/NO 0.37 ± 0.06 2890 ± 330 0.30 ± 0.10 3.3 ± 0.9 
Alg5-PAPA/NO 0.60 ± 0.03 12100 ± 3800 0.10 ± 0.05 2.7 ± 0.1 
Alg5-PAPA-DPTA/NO 0.55 ± 0.04 4890 ± 1300 0.35 ± 0.09 4.8 ± 1.4 
aError represents standard deviation for n ≥ 3 experiments. bTotal NO released. cMaximum 















Table 4.2 Nitric oxide-release properties of NO donor-functionalized alginates in ASM  






t1/2d (mins) tde (h) 
Alg5-DETA/NO 0.18 ± 0.04 670 ± 160 43.0 ± 10.9 5.0 ± 0.3 
Alg5-DPTA/NO 0.19 ± 0.06 3420 ± 960 14.0 ± 1.2  3.1 ± 0.4 
Alg5-SPER/NO 0.27 ± 0.09 2370 ± 1750 5.4 ± 1.6 1.7 ± 0.2 
Alg5-PAPA/NO 0.28 ± 0.05 5990 ± 1480 3.8 ± 0.9 1.2 ± 0.8 
Alg5-PAPA-DPTA/NO 0.29 ± 0.04 4750 ± 1100 8.4 ± 0.6 3.0 ± 0.6 
aError represent standard deviation for n ≥ 3 separate syntheses. bTotal NO released. 











      
 
Figure 4.1 (A) Real-time NO-release profiles for the first 1 h and (B) plot of total NO release 
vs. time for representative biopolymers Alg5-DETA/NO (──), Alg5-DPTA/NO (─ ─), Alg5-
SPER/NO ( ─ ▪ ▪ ), Alg5-PAPA/NO (▪), and Alg5-PAPA-DPTA/NO (─ ▪ ─) measured via 
chemiluminescence in ASM pH 6.5. 
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the negatively charged N-diazeniumdiolates, with concomitant prolonged NO release (i.e., lower  
initial NO flux and longer half-lives) under static conditions.53,54 In the case of NO release in ASM, 
the potential electrostatic interactions between the alginate biopolymers and primary components 
of the media (i.e., mucins and DNA) may destabilize the N-diazeniumdiolate NO donor allowing 
for a larger initial NO amount released and shorter NO-release half-life.3,50,52   
To further elucidate how ASM components may influence the NO-release properties of 
alginates in media, NO-release measurements were collected in mucin and DNA, two of the main 
components of ASM. Alg5-PAPA/NO and Alg5-DPTA/NO biopolymers were selected for this 
study as they represent fast and slow NO-releasing alginates. The hybrid biopolymer containing 
PAPA and DPTA (Alg5-PAPA-DPTA/NO) was also studied as it represents a combination of the 
two systems. As expected, NO release in each of the three biological media (i.e., ASM, mucin, and 
DNA) resulted in a decreased NO flux for the fast releasing Alg5-PAPA/NO in the presence of 
species capable of scavenging NO (Figure 4.2). However, an increase in NO flux was observed in 
both ASM and mucin for Alg5-DPTA/NO. The similarity of the NO-release profiles for Alg5-
DPTA/NO in the two media clearly reflects destabilization of the N-diazeniumdiolate NO donor 
by enhanced electrostatic interactions between the protonated amine groups on alginate and the 
negatively charged moieties on the mucin glycoprotein (i.e., sialic acid residues).32,53–57 The NO-
release profile of the hybrid alginate was unaltered in all media, enabling near constant NO-release 
kinetics despite a decrease in NO totals in the biological media. The combined, enhanced NO flux 
for DPTA and decreased flux for PAPA N-diazeniumdiolates accounts for this phenomenon, 
virtually cancelling the changes related to the biological media altogether. In this regard, the Alg5-






Figure 4.2 Real-time NO-release profiles for the first hour of release for (A) Alg5-DPTA/NO, 
(B) Alg5-PAPA/NO, and (C) Alg5-PAPA-DPTA/NO in PBS (solid), ASM (dash-dot), mucin 




4.3.2 Antibiofilm efficacy 
 Persistent colonization of biofilm-forming pathogens in the airways accounts for ~90% of 
CF patient mortality.10,34 The presence of thick mucus in the CF airways, the EPS matrix, and other 
unique environmental-related factors (e.g., lower oxygen levels) provide additional protection to 
biofilm-based bacteria by limiting the diffusion and action of traditional antibiotics.3,4,58 Indeed, 
slower growth due to viscoelasticity of mucus and the unique biofilm microenvironment (e.g., the 
presence of an oxygen gradient in the mucus that leads to bacteria adaptation to anaerobic 
microenvironments) contributes to the demonstrated resistance of bacteria by these biofilms.8 It is 
thus imperative to evaluate the antibiofilm activity of new therapeutics under conditions that mimic 
CF more accurately (i.e., in ASM under both aerobic and anaerobic conditions). 
 The antibiofilm activity of control and NO-releasing alginates was evaluated against both 
aerobic and anaerobic biofilms of four CF-relevant pathogens: P. aeruginosa, BCC, S. aureus, and 
MRSA.33,34 The minimum concentration of antibacterial agent required to achieve a 5-log 
reduction in viability after 24 h (MBEC24h ) was evaluated for each of the alginate compositions. 
At equivalent concentrations to the MBEC24h, control (non-NO-releasing) alginates did not alter 
the bacterial viability of the biofilms (Figure 4.3). In contrast, treatment with the NO-releasing 
biopolymers led to a 5-log reduction (≥99.999%) in bacterial viability for each of the NO-releasing 
alginates regardless of NO-release properties, implicating NO as the required bactericidal agent 
(Table 4.3). 
Alg5-DPTA/NO, Alg5-SPER/NO, and Alg5-PAPA/NO achieved 5-log biocidal activity at 
16 mg/mL against both P. aeruginosa and BCC under aerobic conditions. The Alg5-DETA/NO 
and Alg5-PAPA-DPTA/NO derivatives deviated from this trend, with the DETA-modified and 









Figure 4.3 Antibiofilm efficacy of Alg5-DETA (circle), Alg5-DPTA (triangle), Alg5-SPER 
(square), Alg5-PAPA (diamond), and Alg5-PAPA-DPTA (cross) against S. aureus biofilms 
under (A) aerobic and (B) anaerobic conditions.  Error bars represent standard deviation of the 





















Table 4.3 Minimum biofilm eradication concentrations (MBEC24h) of NO-releasing 
alginates against aerobic biofilms.a 
Sample 
MBEC24h (mg/mL)a 
P. aeruginosa BCC S. aureus MRSA 
Alg5-DETA/NO 32 32 64 64 
Alg5-DPTA/NO 16 16 32 64 
Alg5-SPER/NO 16 16 32 64 
Alg5-PAPA/NO 16 16 64 32 
Alg5-PAPA-DPTA/NO 4 4 16 16 
Tobramycin 2 2 16 >64 





reported that under static (i.e., PBS with 1 vol% broth) conditions, the slower, sustained NO-
releasing alginates (e.g., Alg5-DETA/NO) facilitated greater biocidal efficacy against biofilms 
compared to faster NO-releasing systems (e.g., Alg5-PAPA/NO).37 With NO scavenging (e.g., NO 
release in ASM), however, the combination of lower NO totals (~0.2 µmol/mg) and slower NO 
release might result in insufficient delivery of the required lethal dose of NO. In this regard, Alg5-
DETA/NO proved to be less effective. Indeed, larger alginate concentrations (32 mg/mL for both 
P. aeruginosa and BCC and 64 mg/mL for both S. aureus and MRSA) were required to achieve 
comparable NO doses and bacteria eradication. With the hybrid Alg5-PAPA-DPTA/NO, the 
slightly higher NO payload (~0.3 µmol/mg), larger NO flux (~5000 ppb/mg), and sustained release 
(td ~3 h) allowed for a more lethal NO delivery and lower MBEC24h values (4 mg/mL for both P. 
aeruginosa and BCC and 16 mg/mL for both S. aureus and MRSA) compared to each of the 
monosubstituted alginates. 
Similar to previous reports,37,59,60 greater concentrations of NO-releasing alginates were 
needed to achieve biocidal action against S. aureus and MRSA biofilms (Table 4.3). The thicker 
peptidoglycan layer, and increased production of polysaccharides and extracellular proteins of 
Gram-positive species in general likely hinder NO diffusion (into the biofilm), necessitating larger 
NO fluxes from the biopolymer to achieve killing.60 These structural differences are hypothesized 
to account for the lower susceptibility of both S. aureus and MRSA biofilms. 
The efficacy of the alginate biopolymers to eradicate the four pathogens was also compared 
to tobramycin. Under similar conditions, both P. aeruginosa and BCC were eradicated at lower 
tobramycin concentrations than those of the NO-releasing alginates (Table 4.3). However, greater 
tobramycin concentrations were required to eradicate Gram-positive bacterial biofilms. Against S. 
aureus, the required tobramycin dose for biocidal action equaled that of Alg5-PAPA-DPTA/NO. 
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Each of the NO-releasing alginates were more efficacious against MRSA, as the Gram-positive 
bacteria showed resistance to tobramycin up to 64 mg/mL. With NO as the implicated bactericidal 
agent, tobramycin concentration was also compared to the NO dose delivered during the bacteria 
killing assay. The NO dose required to achieve antibiofilm activity was derived from both the 
MBEC24h of the alginate samples and the measured total NO released in ASM to compare the 
efficacy of NO to the antibiotic under aerobic conditions (Figure 4.4A). Against each of the four 
pathogens studied, lower initial NO doses relative to the antibiotic were required to achieve 
biocidal activity, demonstrating NO’s potent antimicrobial activity.  
Anaerobically grown biofilms required lower alginate and NO concentrations to achieve 
killing compared to aerobic biofilms (Table 4.4, Figure 4.4B). In contrast, greater tobramycin 
concentrations were necessary to achieve biocidal action under anaerobic versus aerobic 
conditions, following previous reports describing diminished antibiotic activity in low-oxygen 
environments.39,61,62 For S. aureus and MRSA, lower concentrations of the NO-releasing 
biopolymers were also required compared to tobramycin, demonstrating superior antibiofilm 
efficacy compared to the aminoglycoside antibiotic. Analogous to the trends observed under 
aerobic conditions, Alg5-PAPA-DPTA/NO was most effective, achieving a 5-log reduction in 
biofilm bacterial viability at an alginate concentration of only 2 mg/mL against the four pathogens. 
Reighard et al. reported similar results with NO-releasing chitosan oligosaccharides, attributing 
the larger concentration for aerobic conditions to NO scavenging by oxygen and other ROS.39 
Analogously, lower starting NO doses (≤ 140 µg/mL) were needed to treat the anaerobic biofilms 
(Figure 4.4B).  
With tobramycin’s poor activity against S. aureus and MRSA, the antibiofilm activity of 








Figure 4.4 Nitric oxide dose for Alg5-DETA (light gray stripes), Alg5-DPTA/NO (solid light 
gray), Alg5-SPER/NO (dark gray stripes), Alg5-PAPA/NO (solid dark gray), Alg5-PAPA-
DPTA/NO (black stripes) required to treat (A) aerobic and (b) anaerobic biofilms compared 
to tobramycin (solid black). Studies consisted of at least three experiments with error bars 





















Table 4.4. Minimum biofilm eradication concentrations (MBEC24h) of NO-releasing 
alginates against anaerobic biofilms.a 
Sample 
MBEC24h (mg/mL)a 
P. aeruginosa BCC S. aureus MRSA 
Alg5-DETA/NO 8 4 16 4 
Alg5-DPTA/NO 4 4 8 2 
Alg5-SPER/NO 2 2 2 2 
Alg5-PAPA/NO 8 4 8 4 
Alg5-PAPA-DPTA/NO 8 4 16 16 
Tobramycin 4 2 64 >64 




treat infections by Gram-positive bacteria.63 Similar to tobramycin, greater concentrations of 
vancomycin were required to eradicate anaerobic versus aerobic biofilms (Figure 4.5), indicating 
a reduced efficacy under low-oxygen conditions. The doses of NO required to eradicate the 
biofilms were lower for both oxygen levels compared to vancomycin, demonstrating NO’s unique 
ability to remain active as an antimicrobial regardless of oxygen availability. 
4.3.3 Effect of nitric oxide-release kinetics on antibiofilm efficacy 
Biofilm eradication was also studied as a function of NO-release kinetics. P. aeruginosa 
biofilms were treated with equal concentrations of either Alg5-DPTA/NO, Alg5-PAPA/NO, or 
Alg5-PAPA-DPTA/NO at 2 and 4 mg/mL for anaerobic and aerobic growth, respectively (Figure 
4.6). The selected concentrations represent the lowest MBEC24h for the Alg5 systems (i.e., the 
MBEC24h of Alg5-PAPA-DPTA/NO against P. aeruginosa biofilms). Under both aerobic and 
anaerobic conditions, one-time treatment at 2 h with Alg5-DPTA/ NO and Alg5-PAPA/NO 
resulted in a 1- and 2-log reduction in biofilm bacterial viability, respectively. Bacteria viability 
recovered up to ~108 CFU/mL at longer exposure durations for both the PAPA- and DPTA-
modified NO-releasing alginates. The greater total NO of Alg5-PAPA/NO at 2 h resulted in a 
greater viability reduction initially, but the low NO levels released (i.e., below the limit of detection 
of the instrument) thereafter proved insufficient for maintaining lower viability (i.e., killing). On 
the other hand, the low NO totals associated with Alg5-DPTA/NO in ASM led to insufficient NO 
doses after the one-time treatment to achieve any appreciable bacterial killing, thus requiring a 
larger concentration (i.e., 16 mg/mL) to eradicate the biofilm. The results, however, suggest the 
possibility of using multiple treatments with lower concentrations (e.g., 2 or 4 mg/mL) to 










Figure 4.5 Nitric oxide dose for Alg5-DETA (light gray stripes), Alg5-DPTA/NO (solid light 
gray), Alg5-SPER/NO (dark gray stripes), Alg5-PAPA/NO (solid dark gray), Alg5-PAPA-
DPTA/NO (black stripes) required to treat (A) aerobic and (b) anaerobic biofilms of S. aureus 
and MRSA. All starting NO doses were compared to vancomycin (solid black). Studies 







Figure 4.6 Time-based bactericidal efficacy of Alg5-DPTA/NO (circle), Alg5-PAPA-
DPTA/NO (triangle), Alg5-PAPA/NO (square), and tobramycin (cross). Comparison of all 
NO-releasing alginates at equivalent concentrations of (A) 4 mg/mL under aerobic conditions 
and (B) 2 mg/mL under anaerobic conditions. The MBEC24h values under aerobic and 
anaerobic conditions (2 mg/mL and 4 mg/mL, respectively) were used for tobramycin. Studies 




the larger concentration required for one-time treatment. Of course, such a hypothesis must be 
further evaluated pre-clinically and clinically in future work.  
In contrast to both Alg5-PAPA/NO and Alg5-DPTA/NO, the hybrid alginate system 
(Alg5-PAPA-DPTA/NO) elicited an initial 2-log reduction in bacterial viability at the same 
concentration after 2 h for both aerobic and anaerobic biofilms. The combination of greater NO 
totals in ASM (~0.3 µmol/mg) coupled with the sustained NO release (~3 h) by using the hybrid 
biopolymer led to a 5-log reduction after 4 h. Over the same period, tobramycin at its aerobic 
MBEC24h (2 mg/mL) only achieved a 2-log reduction (with an overall 3-log reduction over the 
course of 6 h) suggesting a slower biocidal action mechanism. Similarly, anaerobic biofilms treated 
with tobramycin at the antibiotic’s anaerobic MBEC24h achieved a 2-log reduction over the 6-hour 
treatment period – albeit more slowly. Collectively, the results of this study suggest that the 
combination of a high initial NO flux and sustained NO release is preferred for biofilm eradication. 
Moreover, Alg5-PAPA-DPTA/NO exhibited greater potency against the P. aeruginosa biofilms 
grown in ASM under the two conditions, achieving a 5-log reduction in bacterial viability faster 
than conventional antibiotics. 
 
4.4 Conclusions 
 The antibiofilm action of NO-releasing alginates were clearly demonstrated against the 
four tested, CF-relevant pathogens. Of the different alginate systems, Alg5-PAPA-DPTA/NO 
exhibited the greatest antibacterial action against the test pathogens regardless of biofilm growth 
conditions (MBEC24h starting NO dose of ≤520 µg/mL NO). The NO-based hybrid alginate 
therapeutic also exhibited enhanced efficacy compared to tobramycin and vancomycin, 
demonstrating Alg5-PAPA-DPTA/NO’s promise as an alternative to conventional antibiotics for 
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treating chronic CF infections. Combined with the ability of alginate oligosaccharides to decrease 
mucus viscoelasticity,24,59–61 these results suggest the utility of NO-releasing alginates as a dual-
action CF therapeutic. In particular, NO release may hold great promise for eradicating biofilms 
deeply embedded in the mucus layer where low oxygen concentrations reduce the efficacy of 
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CHAPTER 5: SUMMARTY AND FUTURE DIRECTIONS 
5.1 Summary 
 Cystic fibrosis is an autosomal disease that causes a deficiency in chloride secretion, 
ultimately disrupting mucociliary clearance and the removal of pathogenic bacteria. Chapter 1 
discussed the pathophysiology of CF, current treatment methods, and the potential utility of NO-
based therapies. In healthy patients, the regulation of salt concentration via the CFTR protein 
allows the ASL to function as an innate defense barrier in airways.1–3 However, in the case of CF, 
a defective CFTR results in ASL dehydration, abnormal mucus accumulation, persistent bacterial 
infection, and chronic inflammation that altogether causes respiratory decline and irreversible lung 
damage.4,5 Current treatment methods focus on rehydrating the ASL to improve lung function and 
eradicating bacteria to disrupt the vicious cycle of chronic infection and lung degradation. 
Limitations to these current treatments, including bacterial adaptations and antibiotic resistance, 
motivate the development of non-traditional, novel therapies for the treatment of CF.6 Nitric oxide 
represents an attractive alternative to conventional drugs due to its antimicrobial activity and 
mucolytic action. Inhalation of NO gas demonstrated efficacy in small animal studies and proved 
safe for healthy adults at low concentrations that require multiple repeat exposures and high 
clinical oversight (i.e., hospitalization).7,8 While effective, the inconvenience and high costs 
associated with gaseous NO administration warrant the development of a new delivery system that 
could directly deliver NO to the lungs.  
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As an alternative delivery system, Chapter 2 focused on modifying high and low molecular 
weight alginate with small molecule alkyl amines for subsequent NO donor formation. The 
resulting NO-releasing alginate possessed diverse and tunable NO-release kinetics (0.5-13 h half-
lives) dependent on the structure of the precursor alkyl amine and alginate molecular weight. 
Bactericidal activity against planktonic and biofilm forms of P. aeruginosa and S. aureus was 
dependent on both the NO-release kinetics and molecular weight of the alginate system. Nitric 
oxide-releasing alginate possessing slow, sustained release properties (i.e., DETA- and DPTA-
modified alginate) was found to be more efficacious against bacterial biofilms, requiring lower 
concentration of NO-releasing alginate to elicit biocidal action. Further, low molecular weight 
alginate exhibited antibacterial activity at lower concentrations versus their high molecular weight 
counterparts. The results indicate the potential utility of the alginate biopolymer as a NO-delivery 
scaffold with tunable release kinetics and antibacterial activity. 
Chapter 3 evaluated the impact of NO-releasing alginate on mucus rheology. Treatment of 
mucus with NO-releasing low molecular weight alginate reduced both the viscosity and elasticity 
of the mucus. The reduced viscoelasticity was found to be dependent on NO-release kinetics and 
dose of treatment. Of the NO-releasing alginate biopolymers, the hybrid Alg5-PAPA-DPTA/NO 
was most effective, possessing the necessary NO flux and sustained release to substantially reduce 
the viscoelasticity. Increasing the alginate dose improved efficacy, with high concentrations (~80 
mg/mL) reducing mucus viscosity and elasticity most significantly. All of the NO-releasing 
alginates investigated were more effective at reducing viscoelasticity than chitosan, which 
suggesting a benefit for using a negatively charged biopolymer over a cationic scaffold. The NO-
releasing alginate also exhibited a greater effect than N-acetyl cysteine (NAC), a common 
mucolytic agent, thereby requiring a lower NO dose to achieve the same reductive effect. 
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 Lastly, Chapter 4 demonstrated the use of NO-releasing alginate as a biocidal agent against 
a broad-spectrum of CF-relevant pathogens (i.e., Pseudomonas aeruginosa, Burkholderia cepacia 
complex, Staphylococcus aureus, and methicillin-resistant S. aureus). Distinct alkyl amine 
functional groups allowed for tunable NO storage (0.1-0.3 µmol/mg) and release kinetics (t1/2 0.2-
0.4 h) when measured in biological media that mimics components of CF mucus (i.e., artificial 
sputum media). Following treatment with NO-releasing alginate, it was determined that aerobic 
biofilms required greater NO doses to achieve killing versus that for anaerobic biofilms. The 
hybrid alginate biopolymer, Alg5-PAPA-DPTA/NO, exhibited the most potent antibacterial action 
(NO dose ≤520 µg/mL) regardless of growth conditions. This low dose surpasses that required of 
either tobramycin (≥2000 µg/mL) and vancomycin (≥1000 µg/mL). A time-kill study with P. 
aeruginosa demonstrated that the NO-releasing hybrid alginate achieved biofilm eradication faster 
than tobramycin and at lower concentrations than the mono-substituted biopolymers (i.e., alginate 
modified with only PAPA or DPTA). Overall, the results of this study suggest the use of NO-
releasing alginate in treating biofilm-based infections in CF. 
 
5.2 Future Directions 
The results presented in the previous chapters highlight the potential of biopolymer-based 
NO delivery as a dual-action therapy for CF. While these studies clearly demonstrate both the 
reductive antibacterial and mucolytic activity of NO-releasing alginates, substantial work remains 





5.2.1 Combination therapy with current CF treatments 
Combination therapy is often used for treating pulmonary infections in CF.9–11 While the 
success of this approach using combinations of conventional antibiotics against multidrug-resistant 
pathogens is debated, co-administration of these therapies with NO may be of benefit due to NO’s 
multi-mechanistic antibacterial action and ability to degrade biofilm exopolysaccharide (EPS) 
matrices.12–14 Thus, assessing the utility of NO-releasing alginate as a co-administered CF therapy 
is an essential next step. 
Simultaneous treatment of P. aeruginosa biofilms with the small molecule NO donor 
sodium nitroprusside (SNP) and tobramycin has previously been reported to improve biofilm 
eradication compared to single agent treatment.13 Reduced presence of biofilms in airways was 
also observed when antibiotics (i.e., tobramycin or ceftazidime) were co-administered with inhaled 
NO gas (5-10 ppm for 8 h per day) for CF patients. A recent study by Howlin et al. showed that 
pretreatment of P. aeruginosa biofilms with low doses of NO (~450 nM NO generated from 500 
µm SNP) increased biofilm susceptibility to either tobramycin or a tobramycin-ceftazidime 
combination.12 While the results of these initial studies are promising, a systematic evaluation on 
the effect of NO when used in combination with antibiotics is still necessary. In addition, 
elucidating the influence of both the biopolymeric scaffold used for NO delivery and the NO-
release properties is greatly needed. The possible effects of NO-releasing alginate (i.e., synergistic, 
additive, indifferent, or antagonistic) with a broader range of antibiotics (e.g., tobramycin, 
vancomycin) should be evaluated using combination bactericidal antibiotic tests (i.e., 
checkerboard assays).  Assays should be performed using both planktonic and biofilm forms of 
CF-relevant strains (e.g., multi-drug resistant P. aeruginosa, MRSA) to test the broad-spectrum 
activity of alginate-based NO therapy when combined with other antibacterial agents.  
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Combination time-kill assays performed alongside the checkerboard assays should facilitate 
quantitative determination of the effect of each antibiotic agent in conjunction with NO as a 
function of time. Comparison with the single agent time-kill assays will allow for a better 
understanding as to how NO release influences the overall effect of the NO-based therapy when 
co-administered with antibiotics. 
5.2.2 Biophysical characterization of biofilms and CF sputum 
The impact of NO-releasing alginates on mucus viscoelasticity was also evaluated using 
human bronchial epithelial (HBE) mucus, and the influence of key biopolymer properties (i.e., 
size, charge, NO-release kinetics, and dose) was examined in Chapter 3. Future studies should 
evaluate the ex vivo efficacy of Alg5-PAPA-DPTA/NO, the most effective biopolymer, on CF 
sputum – a truly representative medium containing other key mucus components such as DNA. 
Parallel plate rheology should be used to determine the bulk changes in elasticity and viscosity. A 
comparison with rhDNase I (i.e., Pulmozyme), the most commonly used mucolytic agent 
employed for treating CF, should be carried out to fully ascertain the relative utility of NO-
releasing alginate as a mucolytic therapy. Combination treatments using both NO-based therapy 
and rhDNase I should be investigated to identify any potential synergistic, additive, indifferent, or 
antagonistic activity between the two treatment regiments. The ability of NO-releasing alginate to 
reduce the size of mucins and DNA can be evaluated using electrophoretic separation of CF 
sputum following treatment. Additionally, confocal microscopy of CF sputum samples treated 
with alginate should be used to examine how these materials alter mucin and DNA networks, 




The ability of the NO-based therapeutic to alter the 3D structure of the biofilm EPS matrix 
is also of interest. Rheological studies (e.g., sand-blasted parallel plate, cone and plate, and 
multiple particle tracking rheology) should be conducted to evaluate the impact of NO-releasing 
alginate on the viscoelastic properties of the biofilm EPS matrix. Comparison with other NO-
releasing biopolymers (e.g., chitosan), non-NO-releasing biopolymer controls, and conventional 
antibiotic treatments (e.g., tobramycin, vancomycin) should be carried out and benchmarked. 
As mucociliary clearance is a crucial aspect of the host defense in the airways, particularly 
in removing inhaled pathogens, characterization of how alginate-based NO delivery systems 
impact mucus transport should be performed. Optical coherence tomography (OCT) is a high-
resolution imaging technique that can be used to monitor mucus flow and ciliary beat frequency 
on airway epithelium in vitro.15,16 Human bronchial epithelial cell cultures grown over 
approximately 6 w develop cilia and secrete mucus that accumulates over time.16 As the cells are 
cultured in a circular dish, the accumulated mucus is transported in a rotational pattern. Mucus 
flow imaging and analysis should be performed in cross-sectional slices moving across the center 
of the spiral for untreated culture, and cultures treated with non-NO-releasing (control) and NO-
releasing alginate. The ciliary beat rate should be measured to determine how NO release affects 
the rate of mucus clearance. 
5.2.3 Biopolymeric scaffolds for improved nitric oxide storage and release 
While alginate represents an attractive material for use in pulmonary delivery due to its 
low toxicity and water solubility, it is limited by a relatively lower NO payload compared to other 
macromolecular scaffolds (e.g., dendrimers with total NO ~1 µmol/mg). Developing alternative 
modification strategies for alginate (e.g., modifying the hydroxyl moieties on the biopolymer 
backbone) and/or employing other biopolymeric delivery systems with greater NO payloads could 
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facilitate lower therapeutic doses to eradicate biofilms and reduce mucus viscoelasticity. In this 
regard, a library of NO-releasing biopolymeric systems should be created and evaluated as 
potential CF therapeutics. 
 Hyaluronic acid (HA), an anionic biopolymer found throughout the body composed of 
alternating β-N-acetyl-D-glucosamine and 1,4-linked β-D-glucuronic acid units (Figure 5.1A),17–20 
represents a potential alternative to alginate as a NO delivery scaffold. In nature, HA is found in 
abundance in biological fluids and tissues, and is water soluble at molecular weights up to 2.5 
MDa.17,19 It is an essential component of the extracellular matrix (ECM) in cartilage tissues, 
synovial fluid, umbilical cords, and the vitreous of the eye.18,19 High molecular weight HA plays 
multiple roles within mammalian tissue, including water homeostasis, cell proliferation, and 
wound repair. Low molecular weight HA has been reported to have angiogenic, pro-inflammatory, 
and immunostimulatory properties.17–20 As a consequence of these molecular weight dependent 
roles, HA has been used for a wide range of biomedical applications, including tissue engineering, 
drug delivery, and wound dressings. The biopolymer backbone allows for versatile modification 
chemistries due to its functional groups (i.e., carboxylic acid, primary and secondary alcohols).17 
For example, carbodiimide chemistry can be utilized to impart secondary amine functionalization 
on the carboxylic acid moieties of HA with various alkyl amine functional groups to tune NO 
release properties. Similar to alginates, molecular weight may also influence the NO-release 
properties of HA. While HA is commercially available in a range of molecular weights (~6-1000 
kDa), oxidative degradation could be explored to obtain even smaller biopolymer sizes (i.e., <6 
kDa), similar to alginate and chitosan.21,22 
Another potential biopolymer system of interest is the cyclodextrin (CD) family, which are 








Figure 5.1 Structures of (A) hyaluronic acid and (B) cyclodextrin biopolymers. 
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4)  linkages,23–27 and are highly water soluble, biodegradable, and biocompatible. Due to steric 
effects, α-, β-, and γ-CDs exist in nature with 6, 7, or 8 D-glucose units, respectively (Figure 5.1B). 
Their cyclic structure provides a hydrophobic central cavity that is attractive for the encapsulation 
of poorly water-soluble drugs (e.g., doxorubicin).23–25 A hydrophilic exterior provides enhanced 
water solubility. Of importance, the exterior hydroxyl groups are easily modified with functional 
groups ideal for NO storage and release capabilities.28 The overall amphiphilicity may allow for 
co-delivery of different therapeutic agents used in CF (e.g., antibiotics such as rifampicin and 
ciprofloxacin) with NO for possible synergistic activity. 
 The hydrophilicity, NO-release profiles, antibacterial and mucolytic activity, and 
cytotoxicity for these biopolymers can be further controlled using additional surface 
modifications.28 For example, modification with functional groups such as PAPA can minimize 
interactions with mucus components while amine-terminated modifications such as DPTA or 
SPER could promote such interactions and mitigate NO’s mucolytic effect.  Elemental (CHN) 
analysis, along with 1H and 13C NMR, should be used to confirm the structure and composition of 
the resulting materials. The mucolytic potential and antibacterial efficacy of the NO-releasing 




The work presented in this dissertation describes the potential of nitric oxide (NO) as a 
dual-action CF therapeutic. Alginate was selected as a macromolecular scaffold for NO storage 
and release due to its inherently low toxicity, biocompatibility, water solubility, and ability to 
modulate mucus viscoelasticity. Low molecular weight (~5 kDa) alginates with high initial NO 
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flux and sustained release capabilities significantly altered mucus viscoelasticity at a lower 
concentration than the conventional mucolytic agent NAC. Further, each alginate biopolymer, 
regardless of the alkyl amine modification, also showed greater efficacy for reducing mucus 
viscoelasticity relative to the positively charged chitosan oligosaccharides, demonstrating the 
benefits of using a negatively charged NO delivery biopolymer for CF applications.  Nitric oxide 
released from the alginate biopolymers also exhibited greater biocidal activity against the biofilms 
of four CF-relevant pathogens compared to commercially used antibiotics, indicating NO’s 
potential as a dual-action therapeutic agent. The results of the studies presented here suggest that 
the use of NO-releasing alginates as a single-agent therapeutic may be an attractive alternative to 
currently employed therapies which must be used in combination. To further develop NO-releasing 
alginate as a dual-action therapeutic, additional characterization of the impact of NO-releasing 
alginate on biofilm rheology and mucociliary clearance should be performed. The observations 
derived from the previous chapters will also aid in the design of other novel NO-releasing 
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APPENDIX A:  SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
 
Calculation of % Modification for Alg5-PAPA-DPTA 
 
The % PAPA modification was first determined from the hybrid scaffold by integrating the 1H 
NMR peak at 0.83 ppm corresponding to the methyl terminal group of PAPA (Imethyl): 
% 𝑃𝐴𝑃𝐴 =  
𝐼𝑚𝑒𝑡ℎ𝑦𝑙
3
 𝑥 100 %     (eq. 1) 
From the 1H NMR spectra, PAPA modification for the alginate hybrid scaffold was found to be 
43%. The % N from the PAPA modification was then determined from the % PAPA value as 
follows: 
% 𝑁𝑃𝐴𝑃𝐴 = (% 𝑃𝐴𝑃𝐴 𝑥 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 % 𝑁𝑃𝐴𝑃𝐴) 𝑥 100 %   (eq. 2) 
Where theoretical %NPAPA is the theoretical % N value corresponding to 100 % PAPA 
modification (i.e., 9.6 %) and was determined following the equation below: 
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 % 𝑁𝑃𝐴𝑃𝐴 =  
# 𝑜𝑓 𝑁 𝑖𝑛 𝑃𝐴𝑃𝐴 𝑥 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑁
𝑀𝑊 𝑜𝑓 𝑃𝐴𝑃𝐴−𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐴𝑙𝑔 𝑚𝑜𝑛𝑜𝑚𝑒𝑟
 𝑥 100 %  (eq. 3) 
The % NPAPA was found to have a value of 4.1%. Next, the % N from the DPTA modification 
was calculated by subtracting the % NPAPA from the total % N for the hybrid alginate as 
determined by CHN. 
% 𝑁𝐷𝑃𝑇𝐴 = % 𝑁𝑡𝑜𝑡𝑎𝑙 − % 𝑁𝑃𝐴𝑃𝐴     (eq. 4) 
Using the equation, % NDPTA was found to be 7.1%. The % DPTA modification of the scaffold 
was determined using the equation below: 
% 𝐷𝑃𝑇𝐴 =  
% 𝑁𝐷𝑃𝑇𝐴
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 % 𝑁𝐷𝑃𝑇𝐴 
 𝑥 100 %    (eq. 5) 
Where the theoretical % NDPTA (i.e., 14.1 %) was determined following eq. 2 for the DPTA 
modification. From the equation, the hybrid scaffold had 50% DPTA modification, giving an 








































































































































Figure A.3 Representative UV-vis spectra for secondary amine- (dash) and N-
diazeniumdiolate-modified (solid) (for (A) Alg5-DETA, (B) Alg5-DPTA, (C) Alg5-SPER, 

























Table S3. Reduction in elastic and viscous modulus with respect to untreated 3 wt % HBE mucus 
after treatment for 24 h.a 
Scaffold % reduction in Elastic Modulusb % reduction in Viscous Modulusb 
Alg300 54 ± 4 26 ± 6 
Alg10 51 ± 13 42 ± 14 
Alg5 73 ± 15 64 ± 21 
Alg5-DETA 13 ± 2 14 ± 5 
Alg5-DPTA -8 ± 1 -7 ± 4 
Alg5-PAPA-DPTA 14 ± 1 12 ± 1 
Alg5-PAPA 14 ± 4 8 ± 3 
Alg5-SPER -17 ± 4 -43 ± 10 
Alg1 71 ± 10 77 ± 23 
COS 3 ± 1 -49 ± 4 
COS-EA -48 ± 20 -61 ± 40 
aError represents standard deviation for n ≥ 3 experiments. bReduction in both elastic and  
 
  
Figure A.4 (A) Real time NO-release profiles for the first 1 h and (B) plot of total NO release 
vs. time for representative biopolymers Alg5-DETA/NO (──), Alg5-DPTA/NO (─ ─), Alg5-
PAPA-DPTA/NO (─ ̶ ▪ ─̶ ), Alg5-PAPA/NO (▪), Alg5-SPER/NO ( ─ ▪ ▪ ), and COS-EA/NO 
(•) measured via chemiluminescence in PBS pH 6.5. 
 
















































Figure A.5 Complex viscosity of 3 wt% HBE mucus following treatment with Alg5-DETA 
(black solid), Alg5-DPTA (black horizontal), Alg5-SPER (black diagonal), Alg5-PAPA (gray 
solid), Alg5-PAPA-DPTA (gray horizontal), and COS-EA (gray diagonal). Values presented 
as the mean standard deviation of the mean for n = 3 experiments. Asterisks (*) indicate 










































Figure A.6 Complex viscosity of 3 wt% HBE mucus following treatment with NAC 0.1 wt% 
(black solid), NAC 0.2 wt% (black diagonal), NAC 10 wt% (gray solid), and NAC 20 wt% 
(gray diagonal). Values presented as the mean standard deviation of the mean for n = 3 
experiments. Asterisks (*) indicate significant differences (p < 0.05) relative to untreated 
sample (hollow). 
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